

## UNIVERSIDADE ESTADUAL DE SANTA CRUZ PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIA ANIMAL

ERIK DA SILVA PINTO

# ANÁLISE EPIDEMIOLÓGICA E ESPAÇO-TEMPORAL DA COINFECÇÃO DE LEISHMANIOSES E HIV NO ESTADO DA BAHIA

ILHÉUS – BAHIA 2025

#### ERIK DA SILVA PINTO

## ANÁLISE EPIDEMIOLÓGICA E ESPAÇO-TEMPORAL DA COINFECÇÃO DE LEISHMANIOSES E HIV NO ESTADO DA BAHIA

Dissertação apresentada à Universidade Estadual de Santa Cruz, como parte das exigências para obtenção do título de Mestre em Ciência Animal.

Linha de pesquisa: Biodiversidade, Clínica e Sanidade Animal Subárea: Epidemiologia

Orientadora: Profa. Dra. Anaiá da Paixão Sevá

ILHÉUS – BAHIA 2025

#### ERIK DA SILVA PINTO

## ANÁLISE EPIDEMIOLÓGICA E ESPAÇO-TEMPORAL DA COINFECÇÃO DE LEISHMANIOSES E HIV NO ESTADO DA BAHIA

Ilhéus – BA, 26/02/2025

#### BANCA EXAMINADORA

Dra. Anaiá da Paixão Sevá UESC/DCAA (Orientadora)

Profa. Dra. Débora Rochelly Alves Ferreira UNIFIP/Patos-PB

Prof. Dr. José Angelo Lauletta Lindoso USP/FM

> ILHÉUS – BAHIA 2025

Dedico esta dissertação à minha mãe, Luzia, por apoiar cada etapa da minha jornada acadêmica, e aos pacientes acometidos pelas leishmanioses, que, mesmo anonimamente, tornam-se a essência deste estudo, contribuindo para o avanço do conhecimento e a busca por melhores estratégias de prevenção e tratamento.

#### AGRADECIMENTOS

A Deus, por me permitir chegar a este momento marcante em minha vida, concedendo forças e sabedoria para superar os desafios ao longo da caminhada.

Aos meus pais, José e Luzia, que, apesar das dificuldades e das limitações educacionais, sempre valorizaram o conhecimento e não mediram esforços para me proporcionar uma educação de qualidade.

Às minhas irmãs, Anita, Arani e Sofia, pelo apoio incondicional e incentivo constante, que foram essenciais nos momentos de incerteza e cansaço.

À minha orientadora, Profa. Dra. Anaiá da Paixão Sevá, pelo aceite de orientação, pela paciência e pela disponibilidade em compartilhar seu conhecimento e experiência, contribuindo para a realização deste trabalho.

Aos colegas de mestrado, que fizeram parte desta jornada, em especial ao Ramon Silva Oliveira, pela amizade, apoio constante e por proporcionar leveza e risadas nos momentos mais difíceis.

Aos colegas do LABEP, especialmente a Maíra Kersul e Reizane Lordelo, pela receptividade e prontidão em me auxiliar desde a minha chegada à UESC, tornando o ambiente acadêmico mais acolhedor.

Aos funcionários da Pós-Graduação em Ciência Animal.

À SESAB, pela cessão dos dados que possibilitaram este estudo.

À Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), pela concessão da bolsa de mestrado.

A todos que, de alguma forma, contribuíram para a realização deste trabalho, meus mais sinceros agradecimentos.

"Refresca teu coração. Sofre, sofre, depressa, que é para as alegrias novas poderem vir..." Guimarães Rosa

#### ANÁLISE EPIDEMIOLÓGICA E ESPAÇO-TEMPORAL DA COINFECÇÃO DE LEISHMANIOSES E HIV NO ESTADO DA BAHIA

#### RESUMO

Os objetivos foram avaliar as características epidemiológicas e espaço-temporais da leishmaniose visceral (LV), leishmaniose tegumentar (LT) e HIV em escala espaço-temporal no estado da Bahia, Brasil. Para tanto, incluiu-se identificar e comparar o perfil dos casos isolados e coinfectados, bem como prevalência, letalidade, morbidade, faixa etária, recidivas e abandono de tratamento, além de ilustrar e analisar suas distribuições geográficas. Tratou-se de um estudo descritivo ecológico de série temporal, que analisou os casos entre 2008 e 2022. Os dados sociodemográficos e clínico-epidemiológicos foram coletados do SINAN e organizados para análises descritivas e estatísticas realizadas nos programas R Studio e Jamovi. As tendências temporais de incidência foram analisadas com modelos de regressão joinpoint. Mapas temáticos foram criados no QGIS para representar a distribuição espacial. Entre 2008 e 2022, foram notificados 8.664 casos de LV, com 57,18% confirmados, e 2,30% destes coinfectados com HIV. E no mesmo período, foram notificados 41.303 casos de LT, com 98,40% confirmados e 0,48% coinfectados com HIV. A tendência dos casos de LV foi decrescente de 2014 a 2022 (inclinação: -0,26; IC 95%: -0,32 a -0,20; valor de p: 0,002), enquanto os casos de coinfecção LV/HIV permaneceram estacionários. Os casos de LT apresentaram aumento em 2010 e 2012, mas também apresentaram tendência decrescente após 2013. A coinfecção TL/HIV também apresentou tendência decrescente no período de 2010 a 2013. A análise GLM mostrou que adultos e idosos têm maior chance de coinfecção LV/HIV do que LV isolada, quando comparados a crianças. Homens e moradores de áreas urbanas também apresentaram maior risco de coinfecção, quando comparados a mulheres e moradores de áreas rurais. Dentre os sintomas, 90% dos casos de LV apresentaram febre e 30,4% apresentaram edema, ambos mais comuns na LV isolada quando comparados à coinfecção LV/HIV. Além disso, 8,9% dos casos de coinfecção TLHIV apresentaram presença de dano de mucosa, enquanto 3,8% dos casos de LT isolada apresentaram presença de dano de mucosa. A letalidade da LV aumentou ao longo dos anos, enquanto a letalidade da AIDS diminuiu, mostrando correlação inversa (rho=-0,270, p=0,330, R<sup>2</sup>= 0,000997). Da mesma forma, a letalidade da TL aumentou, enquanto a letalidade da coinfecção TL/HIV diminuiu (rho=-0,549, p=0,034, R<sup>2</sup>=0,176). Os casos de LV foram mais prevalentes nas partes central e oeste do estado, os casos de TL tiveram maior incidência nas regiões sul e oeste do estado, enquanto os casos de HIV se concentraram nas partes costeiras e extremo sul. As coinfecções LV/HIV e TL/HIV ocorreram em locais focais, com a intensidade correspondendo à incidência isolada de LV e TL, respectivamente. Clinicamente, as coinfecções apresentaram maior letalidade em comparação às doenças isoladas, particularmente em populações socioeconomicamente vulneráveis. Os padrões de utilização de medicamentos também diferiram, com o antimonial pentavalente sendo amplamente usado em casos isolados, enquanto a anfotericina B foi mais frequente em coinfecções. As taxas de abandono de tratamento e recidivas foram mais elevadas entre os coinfectados. Fatores como alta temperatura, baixa umidade, urbanização e desigualdades socioeconômicas foram associados à maior incidência de LV e coinfecções LV/HIV. O estudo reforça a importância de intervenções integradas que considerem determinantes sociais, controle vetorial e ampliação do acesso ao diagnóstico e tratamento.

Palavras-chave: AIDS; Leishmania; leishmaniose visceral, leishmaniose tegumentar

#### EPIDEMIOLOGICAL AND SPACE-TIME ANALYSIS OF LEISHMANIASIS AND HIV COINFECTION IN THE STATE OF BAHIA

#### ABSTRACT

The objectives were to evaluate the epidemiological and spatiotemporal characteristics of visceral leishmaniasis (VL), cutaneous leishmaniasis (TL), and HIV on a spatiotemporal scale in the state of Bahia, Brazil. To this end, the study included identifying and comparing the profile of isolated and co-infected cases, as well as prevalence, lethality, morbidity, age range, relapses, and treatment abandonment, in addition to illustrating and analyzing their geographic distributions. This was an ecological descriptive time-series study, which analyzed cases between 2008 and 2022. Sociodemographic and clinical-epidemiological data were collected from SINAN and organized for descriptive and statistical analyses performed in the R Studio and Jamovi programs. Temporal trends in incidence were analyzed with joinpoint regression models. Thematic maps were created in QGIS to represent the spatial distribution. Between 2008 and 2022, 8,664 cases of VL were reported, with 57.18% confirmed, and 2.30% of these co-infected with HIV. And in the same period, 41,303 cases of LT were reported, with 98.40% confirmed and 0.48% co-infected with HIV. The trend in VL cases was decreasing from 2014 to 2022 (slope: -0.26; 95% CI: -0.32 to -0.20; p-value: 0.002), while cases of VL/HIV coinfection remained stationary. LT cases increased in 2010 and 2012, but also showed a decreasing trend after 2013. LT/HIV coinfection also showed a decreasing trend from 2010 to 2013. The GLM analysis showed that adults and the elderly have a higher chance of LV/HIV coinfection than isolated LT, when compared to children. Men and urban residents also had a higher risk of coinfection, when compared to women and rural residents. Among the symptoms, 90% of LT cases presented fever and 30.4% presented edema, both more common in isolated LT when compared to LT/HIV coinfection. In addition, 8.9% of LT/HIV coinfection cases presented mucosal damage, while 3.8% of isolated LT cases presented mucosal damage. The lethality of VL increased over the years, while the lethality of AIDS decreased, showing an inverse correlation (rho=-0.270, p=0.330, R<sup>2</sup>= 0.000997). Similarly, the lethality of LT increased, while the lethality of LT/HIV co-infection decreased (rho=-0.549, p=0.034, R<sup>2</sup>=0.176). VL cases were more prevalent in the central and western parts of the state, LT cases had a higher incidence in the southern and western regions of the state, while HIV cases were concentrated in the coastal parts and extreme south. LT/HIV and LT/HIV co-infections occurred in focal locations, with the intensity corresponding to the isolated incidence of VL and LT, respectively. Clinically, co-infections presented higher lethality compared to isolated diseases, particularly in socioeconomically vulnerable populations. Medication use patterns also differed, with pentavalent antimonial being widely used in isolated cases, while amphotericin B was more frequently used in co-infections. Treatment abandonment and relapse rates were higher among co-infected individuals. Factors such as high temperature, low humidity, urbanization and socioeconomic inequalities were associated with higher incidence of VL and VL/HIV co-infections. The study reinforces the importance of integrated interventions that consider social determinants, vector control and increased access to diagnosis and treatment.

Keywords: AIDS; Leishmania; visceral leishmaniasis, tegumentary leishmaniasis

## LISTA DE ILUSTRAÇÕES

| Figure 1. Division of the Health Region and their Regional Health Centers, of Bahia state, in     |
|---|
| the Northeast Region of Brazil26  |
| Figure 2. Number and frequency of reported cases of VL isolated and in co-infection with HIV,     |
| according to the type of entry and confirmatory status  |
| Figure 3. Number of total VL cases and proportion of VL/HIV co-infection within VL isolated,      |
| by four -month period and year of first symptoms  |
| Figure 4. Trend of the Joinpoint regression coefficient of the incidence of VL and in VL/HIV      |
| co-infection in Bahia, 2008-202232  |
| Figure 5. Age pyramid of new cases of VL and VL/HIV co-infection, according to sex, between       |
| 2007 and 2022, in Bahia, Brazil   |
| Figure 6. Prevalence and respective 95% confidence intervals of clinical signs and symptoms       |
| of cases of VL and in VL/HIV coinfection, between 2007 and 2022 in Bahia state, Brazil34          |
| Figure 7. Characteristics associated with schooling (A) and age group (B) to the occurrence of    |
| VL/HIV, VL isolate, and HIV isolate co-infection from 2008 to 2022 in the state of Bahia36        |
| Figure 8. Number and frequence of race/color of patients with of VL/HIV, VL isolate, and HIV      |
| isolate co-infection, from 2008 to 2022 in the state of Bahia                                     |
| Figure 9. Annual lethality rate of cases of VL, VL/HIV and AIDS in the state of Bahia, between    |
| 2008 and 202246   |
| Figure 10. Spatial distribution of incidences of cases VL, HIV and VL/HIV co-infection by         |
| municipality in Bahia from 2008 to 202247   |
| Figure 11. Moran's local indices of incidence of VL, HIV and VL/HIV cases (mean between           |
| 2008 and 2022), by municipality in Bahia state, Brazil  |
| Figure 12. Local bivariate spatial correlation of the incidences of: $A - VL/HIV$ coinfection and |
| VL isolated; B - VL/HIV and HIV coinfection isolated; C - VL isolated and HIV isolated in the     |
| state of Bahia, Brazil, 2008-202249   |
| Figure 13. Local bivariate spatial correlation of the incidence of VL/HIV co-infection with: A    |
| - Municipal Human Development Index (MHDI); B - Illiteracy rate; C - Percentage of the            |
| urban population residing in households connected to the water supply network; D – Percentage     |
| of the urban population served by regular household waste collection services; E - Percentage     |

| of those employed in the agricultural sector; F - Percentage of those employed in the mineral    |
|--|
| extractive sector, in the state of Bahia, period 2008-2022                                       |
| Figure 14. Local bivariate spatial correlation of the incidence of VL/HIV co-infection with: A   |
| - Mean Rainfall; B - Average Temperature; C - Average Humidity; D - Gross Domestic               |
| Product (GDP); E - Gini Index; F - Unemployment Rate, in the state of Bahia, period 2008-        |
| 2022   |
| Figure 15. Local bivariate spatial correlation of the incidence of VL/HIV co-infection with: A   |
| - Percentage of Poor; B - Percentage of Vulnerable to Poverty; C - Percentage of Extremely       |
| Poor; D - Percentage of people enrolled in CadÚnico or beneficiaries of Bolsa Família, in the    |
| state of Bahia, period 2008-202253   |
| Figure 16. Description of the number of reports and frequency of cases of TL isolated and in     |
| co-infection with HIV, according to the type of entry and confirmatory status                    |
| Figure 17. Number of total TL cases and proportion of TL/HIV co-infection within TL isolated,    |
| by four -month period and year of first symptoms56   |
| Figure 18. Trend of the Joinpoint regression coefficient of the incidence of TL and in TL/HIV    |
| co-infection in Bahia, 2008-202257   |
| Figure 19. Age pyramid of new cases of TL and TL/HIV co-infection, according to sex,             |
| between 2007 and 2022, in Bahia, Brazil  |
| Figure 20. Characteristics associated with schooling (A) and age group (B) to the occurrence     |
| of TL/HIV, TL isolate, and HIV isolate co-infection from 2008 to 2022 in the state of Bahia.     |
|  |
| Figure 21. Characteristics associated with race/color to the occurrence of TL/HIV, TL isolate,   |
| and HIV isolate co-infection from 2008 to 2022 in the state of Bahia                             |
| Figure 22. Annual lethality rate of TL, TL/HIV co-infection and AIDS in the state of Bahia.      |
|  |
| Figure 23. Annual lethality rate of TL, TL/HIV co-infection and AIDS in the state of Bahia,      |
| Brazil67   |
| Figure 24. Spatial distribution of incidences of TL, HIV and TL/HIV coinfection by               |
| municipality in Bahia from 2008 to 2022  |
| Figure 25. Moran's local indices of incidence of TL, HIV and TL/HIV co-infection                 |
| Figure 26. Local bivariate spatial correlation of the incidences of: A - TL/HIV co-infection and |
| TL isolated; B - TL/HIV and HIV co-infection isolated; C - TL isolated and HIV isolated in the   |
| state of Bahia, 2008-2022  |

| Figure 27. Local bivariate spatial correlation of the incidence of TL/HIV co-infection with: A |
|--|
| - Municipal Human Development Index (MHDI); B - Illiteracy rate; C - Percentage of the         |
| urban population residing in households connected to the water supply network; D - Percentage  |
| of the urban population served by regular household waste collection services; E - Percentage  |
| of those employed in the agricultural sector; F - Percentage of those employed in the mineral  |
| extractive sector, in the state of Bahia, period 2008-2022                                     |
| Figure 28. Local bivariate spatial correlation of the incidence of TL/HIV co-infection with: A |
| - Mean Rainfall; B - Average Temperature; C - Average Humidity; D - Gross Domestic             |
| Product (GDP); E - Gini Index; F - Unemployment Rate, in the state of Bahia, period 2008-      |
| 2022   |
| Figure 29. Local bivariate spatial correlation of the incidence of TL/HIV co-infection with: A |
| - Percentage of Poor; B - Percentage of Vulnerable to Poverty; C - Percentage of Extremely     |
| Poor; D - Percentage of people enrolled in CadÚnico or beneficiaries of Bolsa Família, in the  |
| state of Bahia, period 2008-202274   |
|  |

## LISTA DE TABELAS

| Table 1. Characteristics of initial drug administered, type of entry, types of diagnosis, and  |
|--|
| evolution in VL/HIV and VL coinfection from 2008 to 2022 in the State of Bahia40               |
| Table 2. Comparison of the initial drug administered with associated characteristics in VL     |
| isolated from 2008 to 2022 in the State of Bahia   |
| Table 3. Comparison of the initial drug administered with associated characteristics in VL/HIV |
| co-infection from 2008 to 2022 in the State of Bahia   |
| Table 4. Characteristics of initial drug administered, type of entry, types of diagnosis, and  |
| evolution in TL/HIV and TL coinfection from 2008 to 2022 in the State of Bahia64               |

## LISTA DE ABREVIATURAS, SIGLAS E SÍMBOLOS

| AIDS           | Acquired Immunodeficiency Syndrome              |
|----------------|---|
| AAPC           | Average Annual Percent Change                   |
| APC            | Annual Percent Change                           |
| CI             | Confidence Interval                             |
| DTNs           | Doenças Tropicais Negligenciadas                |
| GDP            | Gross Domestic Product                          |
| HIV            | Human Immunodeficiency Virus                    |
| IBGE           | Instituto Brasileiro de Geografia e Estatística |
| IFAT           | Indirect Fluorescent Antibody Test              |
| IMG            | Moran's Global Autocorrelation Index            |
| ISCIII         | Instituto de Salud Carlos III (Espanha)         |
| LISA           | Local Indicators of Spatial Association         |
| LT             | Leishmaniose Tegumentar                         |
| LT/HIV         | Coinfecção Leishmaniose Tegumentar e HIV        |
| LV             | Leishmaniose Visceral                           |
| LV/HIV         | Coinfecção Leishmaniose Visceral e HIV          |
| MHDI           | Municipal Human Development Index               |
| NTDs           | Neglected Tropical Diseases                     |
| R <sup>2</sup> | Coefficient of Determination                    |
| SD             | Standard Deviation                              |
| SESAB          | Secretaria da Saúde do Estado da Bahia          |
| SIG            | Sistemas de Informação Geográfica               |
| SINAN          | Sistema de Informação de Agravos de Notificação |
| SUS            | Sistema Único de Saúde                          |
| TARV           | Terapia Antirretroviral                         |
| TL             | Tegumentary Leishmaniasis                       |
| TL/HIV         | Coinfection Tegumentary Leishmaniasis and HIV   |
| UNAIDS         | Joint United Nations Programme on HIV/AIDS      |
| VL             | Visceral Leishmaniasis                          |
| VL/HIV         | Coinfection Visceral Leishmaniasis and HIV      |
| WHO            | World Health Organization                       |
| X²             | Chi-Square Test                                 |
|                |   |

## SUMÁRIO

| 1 INTRODUÇÃO  | 13          |
|---|-------------|
| 2 OBJETIVO GERAL  | 14          |
| 3 OBJETIVOS ESPECÍFICOS   | 14          |
| 4 REVISÃO DE LITERATURA   | 15          |
| 4.1 Leishmaniose Visceral e Leishmaniose Tegumentar Americana           | 15          |
| 4.2 Vírus da Imunodeficiência Humana (HIV) e a Coinfecção com as Leishi | nanioses 17 |
| 4.3 Geoprocessamento em Saúde   |             |
| 5 ARTIGO  | 19          |
| Abstract  | 20          |
| Introduction  | 22          |
| Material and Methods  | 25          |
| Results   |             |
| Discussion  | 75          |
| Conclusion  |             |
| REFERÊNCIAS   | 85          |
| ANEXO A - Comitê de Ética em Pesquisa                                   | 99          |

#### 1 INTRODUÇÃO

As Doenças Tropicais Negligenciadas (DTNs) afetam mais de um bilhão de pessoas em todo o mundo, impactando principalmente populações vulneráveis, sem acesso adequado a serviços de saúde e infraestrutura básica (BANGERT *et al.*, 2017; MAHESHWARI; BANDYOPADHYAY, 2020). Essas doenças representam um desafio sanitário, social e econômico significativo, sendo agravadas por fatores como mudanças climáticas, conflitos, migração e urbanização acelerada (EHRENBERG; AULT, 2005; HOTEZ, 2013).

Dentre as DTNs, as leishmanioses são infecções parasitárias causadas por protozoários do gênero *Leishmania*, transmitidos por vetores flebotomíneos. No Brasil, as duas principais formas clínicas da doença são a leishmaniose visceral (LV), que acomete órgãos internos e pode ser fatal se não tratada, e a leishmaniose tegumentar (LT), que afeta pele e mucosas, podendo causar lesões desfigurantes (WHO, 2019). O Brasil é um dos países com maior carga de leishmanioses no mundo, e a Bahia se destaca como um dos estados mais afetados, com alta incidência e ampla distribuição geográfica da doença (MACHADO *et al.*, 2021a).

A coinfecção *Leishmania*/HIV tem se tornado uma preocupação crescente, especialmente em regiões endêmicas para ambas as doenças. A imunossupressão causada pelo HIV predispõe os indivíduos à infecção por Leishmania e favorece o agravamento da doença, reduzindo a eficácia do tratamento e aumentando a letalidade dos casos (OKWOR; UZONNA, 2013). Estudos indicam que a coinfecção apresenta desafios adicionais para o diagnóstico e manejo clínico, além de exigir estratégias específicas de vigilância epidemiológica (SOUSA-GOMES; ROMERO; WERNECK, 2017).

Diante desse cenário, é fundamental compreender a distribuição epidemiológica, espacial e temporal da coinfecção *Leishmania*/HIV no estado da Bahia. O estudo dessas interações permite identificar áreas de maior risco, orientar políticas públicas e aprimorar estratégias de vigilância e controle da doença, contribuindo para ações mais eficazes em saúde pública.

#### **2 OBJETIVO GERAL**

Avaliar as características epidemiológicas e espaço-temporais da coinfecção entre leishmanioses e HIV, bem como das formas isoladas das leishmanioses, no estado da Bahia.

#### **3 OBJETIVOS ESPECÍFICOS**

- Caracterizar e comparar o perfil epidemiológico dos casos de leishmanioses isoladas e em coinfecção com HIV, considerando prevalência, letalidade, morbidade, faixa etária, recidivas e abandono de tratamento;

 Identificar a distribuição geográfica das leishmanioses isoladas e em coinfecção com HIV;

- Detectar os fatores ambientais, climáticos e socioeconômicos associados aos casos de leishmanioses isoladas e em coinfecção com HIV;

- Relacionar a ocorrência das leishmanioses isoladas e em coinfecção com HIV aos municípios de residência e de notificação dos casos.

#### 4 REVISÃO DE LITERATURA

#### 4.1 Leishmaniose Visceral e Leishmaniose Tegumentar Americana

As leishmanioses são ocasionadas por diversas espécies do gênero *Leishmania*, apresentando as mais variadas características clínicas, que vão desde a úlceras cutâneas até infecções em órgãos viscerais, principalmente na medula óssea, fígado e baço (STEVERDING, 2017). Clinicamente, é dividida em leishmaniose visceral (LV) e tegumentar americana (LT), sendo essa última apresentando a forma cutânea e mucocutânea (BURZA; CROFT; BOELAERT, 2019).

Mundialmente classificadas como doenças tropicais negligenciadas, as leishmanioses já infectaram mais de 12 milhões de pessoas em todo o mundo (INCEBOZ, 2019). Atrelado a essa perspectiva, Leishmania é um protozoário parasito unicelular transmitido por fêmeas de flebotomíneos do gênero Lutzomyia. Este parasito apresenta um ciclo de vida dimórfico, alternando entre a forma promastigota (móvel), presente no vetor, e a forma amastigota (intracelular e imóvel), encontrada nos hospedeiros infectados, incluindo humanos e outros mamíferos (KUMARI *et al.*, 2021; TORRES-GUERRERO *et al.*, 2017).

No Brasil, as principais espécies de *Leishmania* causadoras da LV são *L. chagasi, L. donovani* e *L. infantum*, ocorrendo de forma endêmica no País (AGUIAR; RODRIGUES, 2017). A mesma pode apresentar uma condição clínica fatal, por lesionar os órgãos viscerais do hospedeiro humano e animal. Além de sintomas inespecíficos, o principal quadro clínico é caracterizado por febre e esplenomegalia associadas ou não a hepatomegalia (LIMA *et al.*, 2019; STEVERDING, 2017).

A LT no Brasil é causada pelos agentes *Leishmania amazonensis*, *L. braziliensis* e *L. guyanensis* (INCEBOZ, 2019). Clinicamente, a doença se manifesta por lesões ou úlceras cutâneas, frequentemente localizadas em áreas da pele mais expostas, como nariz, mãos, antebraços e pernas. No entanto, em formas difusas, as lesões podem surgir em regiões não expostas à picada do vetor. Nos casos mucocutâneos, ocorrem lesões metastáticas, com inflamação dos tecidos moles da boca, nariz, laringe e faringe (THAKUR; JOSHI; KAUR, 2020).

As leishmanioses continuam sendo doenças infecciosas de extrema preocupação em diversos países endêmicos (ORGANIZAÇÃO PAN-AMERICANA DE SAÚDE, 2021).

Embora tenha havido uma redução no número de casos de LV, a doença ainda causa impacto significativo nas regiões mais desfavorecidas desses países (SASIDHARAN; SAUDAGAR, 2021).

A LV foi inicialmente registrada no início do século XX na América Latina, com ocorrência restrita a aldeias rurais. No entanto, a partir de 1981, observou-se a urbanização dessa parasitose no Brasil, com a disseminação do parasito para cidades próximas. Nas décadas seguintes, esse processo levou ao aumento do número de casos em áreas urbanas, de modo que, em determinado período, a proporção de infecções urbanas superou as rurais. Estima-se que, ao longo dos anos, a LV tenha acometido mais de cem mil habitantes em diversas cidades brasileiras (COSTA, 2008; WERNECK *et al.*, 2007).

No Brasil, a LV apresenta uma distribuição heterogênea, com maior incidência nas regiões Norte, Nordeste e Centro-Oeste (BRUHN *et al.*, 2024). Entre os estados mais afetados, a Bahia se destaca como um dos principais focos da doença, registrando alta endemicidade em diversas áreas. Ao analisar a situação no estado, constata-se uma disseminação abrangente da LV, com maior concentração de casos na região central. Além disso, essa área apresenta alta vulnerabilidade social e baixos índices de desenvolvimento humano, fatores que contribuem para a persistência e expansão da doença (ANDRADE; SOUZA; CARMO, 2022).

Dentre os casos da LV, há uma prevalência maior no sexo masculino, especialmente em crianças menores de 9 anos, em populações com menor nível de escolaridade ou que ainda não frequentaram a escola, e em residentes de áreas urbanas (MARTINS-MELO *et al.*, 2014a; REIS *et al.*, 2017). Quando analisamos as opções de tratamento disponíveis, fica claro que a LV carece de alternativas terapêuticas inovadoras. Essa falta de progresso destaca a condição da LV como uma doença tropical negligenciada, uma vez que os estudos mais avançados se baseiam no uso de compostos já aprovados para uso clínico, seja em combinação ou não com compostos "redescobertos" (SANGENITO *et al.*, 2019).

Dentre os países com casos de LT, o Brasil figura entre os dez que respondem por mais de 70% dos casos (WHO, 2020). Ela se caracteriza por ser uma doença endêmica no estado da Bahia, localizado no Nordeste do Brasil (SEVÁ *et al.*, 2023). Além disso, tem havido um aumento significativo no número de casos da forma mais grave da doença, uma redução na eficácia dos tratamentos com antimoniais e alterações na composição demográfica da população afetada (JIRMANUS *et al.*, 2012; SESAB, 2024).

A LT apresenta uma prevalência predominante em pacientes do sexo masculino e em populações pardas. Além disso, a faixa etária mais afetada no país é entre 20 e 39 anos. Em relação à escolaridade, observa-se que a maior proporção de casos ocorre entre indivíduos que possuem apenas o ensino fundamental (LOPES *et al.*, 2023).

Por fim, as leishmanioses são doenças complexas que tem sido um desafio para a humanidade ao longo dos séculos (BENCHIMOL; JOGAS JUNIOR, 2020). No entanto, existe a possibilidade de alcançar a eliminação das leishmanioses em algumas décadas, caso novas pesquisas explorando abordagens mais eficazes no tratamento da doença sejam desenvolvidas. Por fim, os esforços conjuntos da comunidade política e científica podem levar a um mundo livre do parasita *Leishmania* (SASIDHARAN; SAUDAGAR, 2021).

#### 4.2 Vírus da Imunodeficiência Humana (HIV) e a Coinfecção com as Leishmanioses

A coinfecção entre o HIV e as leishmanioses representa um desafio significativo para a saúde pública devido à sua apresentação clínica insidiosa e ao impacto no sistema imunológico. Tanto o HIV quanto a LV/LT possuem a capacidade de estabelecer infecções assintomáticas e comprometer a resposta imunológica do hospedeiro. Além disso, a interação entre essas doenças pode potencializar a progressão da infecção por HIV, acelerando a manifestação da Síndrome da Imunodeficiência Adquirida (AIDS), ao mesmo tempo em que favorece a disseminação do parasito da leishmaniose no organismo. Como consequência, indivíduos coinfectados podem apresentar maior risco de recorrência da LV/LT e de agravamento do quadro imunológico, tornando-se potenciais reservatórios do parasita (FERREIRA *et al.*, 2018).

A infecção pelo HIV é endêmica em diversas regiões do mundo e, com a sua disseminação para áreas rurais, aliada à expansão da leishmaniose para regiões suburbanas, há uma crescente sobreposição geográfica dessas doenças. Esse fenômeno tem resultado no aumento da incidência da coinfecção por *Leishmania*/HIV. Casos de coinfecção foram registrados em 35 países, sendo que a maioria dos estudos descreve a associação entre LV e HIV, enquanto há menor número de pesquisas abordando a coinfecção entre LT e HIV (NGOUATEU *et al.*, 2012).

No que se refere ao tratamento, atualmente não há protocolos específicos e padronizados para a abordagem da coinfecção *Leishmania*/HIV. Os fármacos antileishmania, como os antimoniais pentavalentes, a anfotericina B lipossomal e a miltefosina, apresentam eficácia reduzida em indivíduos coinfectados, além de estarem associados a altas taxas de recidiva e mortalidade (LINDOSO *et al.*, 2018). Dessa forma, a recomendação atual baseia-se no uso da terapia antirretroviral (TARV) para o controle do HIV, combinada com esquemas terapêuticos individualizados para a leishmaniose, considerando fatores como resposta clínica, efeitos adversos e condições do paciente. Diante desse cenário, torna-se essencial a realização de estudos para aprimorar as estratégias terapêuticas, incluindo a avaliação de novas combinações farmacológicas e protocolos específicos para essa população vulnerável.

#### 4.3 Geoprocessamento em Saúde

O geoprocessamento engloba diversas técnicas que abrangem obtenção, processamento, manipulação e representação de informações espaciais. As principais ferramentas utilizadas nesse contexto são o sensoriamento remoto, estatística espacial, a cartografia digital e os sistemas de informação geográfica (SIG). O SIG desempenha um papel fundamental ao possibilitar a realização de análises espaciais. Utilizando tais técnicas, é viável identificar e descrever os padrões geográficos presentes em um conjunto de dados (BRASIL, 2006).

Na área da saúde, as técnicas de análise espacial têm sido cada vez mais aplicadas para compreender a distribuição de doenças e os fatores ambientais associados. Essas análises permitem avaliar condições como poluição, desmatamento e mudanças no uso do solo, que podem influenciar a propagação de enfermidades em diferentes contextos urbanos e rurais. Além disso, aspectos socioeconômicos, como condições de moradia, acesso a serviços de saúde, emprego, superlotação e estilo de vida, também são considerados, uma vez que impactam diretamente a saúde da população. Do ponto de vista epidemiológico, essas ferramentas possibilitam a identificação de áreas de risco, a modelagem da distribuição espacial dos fatores associados a determinadas patologias e a formulação de estratégias mais eficazes para vigilância e controle. A utilização de mapas e outros recursos analíticos contribui para a visualização dos indicadores de saúde, apoiando a tomada de decisão em políticas públicas (BARBOSA *et al.*, 2014; MACHADO *et al.*, 2021a; ROQUETTE; NUNES; PAINHO, 2018).

#### **5 ARTIGO**

## EPIDEMIOLOGICAL AND SPATIO-TEMPORAL ANALYSIS OF CO-INFECTION OF LEISHMANIASIS AND HIV IN BAHIA STATE, BRAZIL

(A submeter: PLOS Neglected Tropical Diseases)

| 1  | Epidemiological and spatio-temporal analysis of co-infection of leishmaniasis and HIV in              |
|----|---|
| 2  | Bahia state, Brazil   |
| 3  |   |
| 4  | Erik da Silva Pinto <sup>1*</sup> , Eugenia Carrillo <sup>2</sup> , Anaiá da Paixão Sevá <sup>1</sup> |
| 5  |   |
| 6  | <sup>1</sup> Department of Agricultural and Environmental Sciences (DCAA), UESC, Ilhéus, Bahia,       |
| 7  | Brazil.   |
| 8  | <sup>2</sup> Spanish National Center for Microbiology, Instituto de Salud Carlos III (ISCIII),        |
| 9  | Majadahonda, Madrid, Spain.   |
| 10 |   |
| 11 | *Corresponding author   |
| 12 | E-mail: eriksp.medvet@gmail.com (ESP)   |
| 13 |   |
| 14 | Abstract  |
| 15 | The objectives were to evaluate the epidemiological and spatiotemporal characteristics of             |
| 16 | visceral leishmaniasis (VL), cutaneous leishmaniasis (TL), and HIV on a spatiotemporal scale          |
| 17 | in the state of Bahia, Brazil. To this end, the study included identifying and comparing the          |
| 18 | profile of isolated and co-infected cases, as well as prevalence, lethality, morbidity, age range,    |
| 19 | relapses, and treatment abandonment, in addition to illustrating and analyzing their geographic       |
| 20 | distributions. This was an ecological descriptive time-series study, which analyzed cases             |
| 21 | between 2008 and 2022. Sociodemographic and clinical-epidemiological data were collected              |
| 22 | from SINAN and organized for descriptive and statistical analyses performed in the R Studio           |
| 23 | and Jamovi programs. Temporal trends in incidence were analyzed with joinpoint regression             |
| 24 | models. Thematic maps were created in QGIS to represent the spatial distribution. Between             |
| 25 | 2008 and 2022, 8,664 cases of VL were reported, with 57.18% confirmed, and 2.30% of these             |
| 26 | co-infected with HIV. And in the same period, 41,303 cases of LT were reported, with 98.40%           |

27 confirmed and 0.48% co-infected with HIV. The trend in VL cases was decreasing from 2014 28 to 2022 (slope: -0.26; 95% CI: -0.32 to -0.20; p-value: 0.002), while cases of VL/HIV co-29 infection remained stationary. LT cases increased in 2010 and 2012, but also showed a 30 decreasing trend after 2013. LT/HIV coinfection also showed a decreasing trend from 2010 to 31 2013. The GLM analysis showed that adults and the elderly have a higher chance of LV/HIV 32 coinfection than isolated LT, when compared to children. Men and urban residents also had a 33 higher risk of coinfection, when compared to women and rural residents. Among the symptoms, 34 90% of LT cases presented fever and 30.4% presented edema, both more common in isolated 35 LT when compared to LT/HIV coinfection. In addition, 8.9% of LT/HIV coinfection cases 36 presented mucosal damage, while 3.8% of isolated LT cases presented mucosal damage. The 37 lethality of VL increased over the years, while the lethality of AIDS decreased, showing an inverse correlation (rho=-0.270, p=0.330, R<sup>2</sup>= 0.000997). Similarly, the lethality of LT 38 39 increased, while the lethality of LT/HIV co-infection decreased (rho=-0.549, p=0.034, 40  $R^2$ =0.176). VL cases were more prevalent in the central and western parts of the state, LT cases 41 had a higher incidence in the southern and western regions of the state, while HIV cases were 42 concentrated in the coastal parts and extreme south. LT/HIV and LT/HIV co-infections 43 occurred in focal locations, with the intensity corresponding to the isolated incidence of VL and 44 LT, respectively. Clinically, co-infections presented higher lethality compared to isolated 45 diseases, particularly in socioeconomically vulnerable populations. Medication use patterns 46 also differed, with pentavalent antimonial being widely used in isolated cases, while 47 amphotericin B was more frequently used in co-infections. Treatment abandonment and relapse 48 rates were higher among co-infected individuals. Factors such as high temperature, low 49 humidity, urbanization and socioeconomic inequalities were associated with higher incidence of VL and VL/HIV co-infections. The study reinforces the importance of integrated 50

interventions that consider social determinants, vector control and increased access to diagnosisand treatment.

53 Keywords: AIDS; Leishmania; visceral leishmaniasis, tegumentary leishmaniasis

54

#### 55 Introduction

Neglected Tropical Diseases (NTDs) affect more than one billion people worldwide,
who are from the most vulnerable populations, without distinction of economic class or income
(BANGERT *et al.*, 2017; MAHESHWARI; BANDYOPADHYAY, 2020) In this sense, NTDs
become a challenge for the health, social, and economic development of countries, in which
they are exacerbated by changes in the global scenario, such as climate change, conflicts,
migration, and urbanization processes (EHRENBERG; AULT, 2005; HOTEZ, 2013)

Among one of the main NTDs, leishmaniasis stands out, with a high number of cases in several countries around the world (WHO, 2019) These are diseases that present little pharmacological alternative for clinical treatment, in addition to requiring continuous patient monitoring (SANGENITO *et al.*, 2019) It is worth noting that only a small portion of patients adhere to treatment, which requires specialized health services, located in urban centers, in addition to promoting exposure to the risks of side effects and toxicological effects, due to the long period of medication use (CHARLTON *et al.*, 2018; SANGENITO *et al.*, 2019)

Leishmaniasis is caused by protozoa of several species of *Leishmania*, presenting the
most varied clinical characteristics, ranging from cutaneous and/or mucocutaneous ulcers,
characterized as tegumentary leishmaniasis (TL), to lesions in visceral organs, especially bone
marrow, liver, and spleen, characterized as visceral leishmaniasis (VL) (BURZA; CROFT;
BOELAERT, 2019; STEVERDING, 2017).

In Brazil, the main species of *Leishmania* that causes VL is *L. infantum chagasi* (WHO,
2010) This disease generates a fatal clinical condition, especially if left untreated
(MADALOSSO *et al.*, 2012; MAIA-ELKHOURY *et al.*, 2019) Epidemiologically, some

municipalities in the Northeast and North regions of the country with high relative risk for the development of VL stand out (MELO *et al.*, 2023) The state of Bahia is located in the Northeast of Brazil, and a wide spatial dispersion of VL can be seen in it. Especially in the central region of the state, with the highest incidence of VL, it is an area that concentrates high social vulnerability and low human development (ANDRADE; SOUZA; CARMO, 2022)

82 Studies indicate a higher prevalence of VL in males, especially in children under 9 years 83 of age, in populations with a lower level of education or who have not yet attended school, and 84 in residents of urban areas (MARTINS-MELO *et al.*, 2014a; REIS *et al.*, 2017)

Regarding TL in Brazil, the causative species are *L. amazonensis*, *L. braziliensis*, and *L. mexicana* (BRASIL, 2023) Such as cause clinical lesions such as prominent ulcers in the
areas of the skin (such as nose, hands, forearms, legs) where the insect vector bite occurred.
However, mucocutaneous cases may occur, with metastatic lesions, with inflammation of the
soft tissues of the mouth, nose, larynx and pharynx (THAKUR; JOSHI; KAUR, 2020)

It is worth considering that Brazil is among the ten countries that account for more than 70% of TL cases, and in the state of Bahia it is an endemic disease (WHO, 2020) In addition, there has been a significant case series of the most severe form and a reduction in the efficacy of antimonial treatments (JIRMANUS *et al.*, 2012)

TL has a predominant incidence in male patients and in brown populations. In addition, the most affected age group in the country is between 20 and 39 years old. Regarding education, it is observed that the highest proportion of cases occurs among individuals who have only elementary education (LOPES *et al.*, 2023)

Regarding the severity of leishmaniasis, co-infection with the human immunodeficiency
virus (HIV) stands out. HIV infection is an important public health problem worldwide
(UNAIDS, 2023) With the immunosuppressive effect of HIV, people affected by *Leishmania*are also predisposed to the worsening of the parasitological disease (OKWOR; UZONNA,

102 2013) Thus, several studies have observed that the lethality of VL/HIV co-infection is higher 103 when compared to isolated parasite infection, emphasizing the importance of integrated 104 approaches in the diagnosis and treatment of these infections (MACHADO *et al.*, 2021a; 105 SOUSA-GOMES; ROMERO; WERNECK, 2017) In addition, the coexistence of HIV and VL 106 presents a significant risk due to asymptomatic infection that goes unnoticed. Both HIV and 107 VL share similar characteristics, such as the ability to cause asymptomatic infection and 108 suppress the immune system (FERREIRA *et al.*, 2018)

Regarding co-infection between TL and HIV, changes in the size of ulcers are reported, in addition to therapeutic failures and recurrences of the disease, modifying the clinical and therapeutic course of TL (GUERRA *et al.*, 2011). However, there are no studies in the literature describing the lethality rates of TL/HIV, emphasizing the need to know these epidemiological indicators.

114 In Brazil, the current spatial behavior of VL demonstrates an increase in the number of 115 priority municipalities, concentrated in the states of Tocantins, Maranhão, Piauí, and Mato 116 Grosso do Sul, as well as areas of Pará, Ceará, Piauí, Alagoas, Pernambuco, Bahia, São Paulo, 117 Minas Gerais, and Roraima (MELO et al., 2023) Regarding TL, it presents a scenario of 118 concentration of cases in the North region, with the state of Acre leading the incidence, in 119 addition to Mato Grosso, Maranhão and Bahia (BELO et al., 2023) However, there is a lack of 120 studies that are specifically dedicated to the analysis of the spatial patterns of co-infection 121 between leishmaniasis and HIV in Bahia.

There are several epidemiological studies on leishmaniasis that have used spatial analysis to identify regions at higher risk for the disease (MACHADO *et al.*, 2020a; NUNES *et al.*, 2020; SEVÁ *et al.*, 2017) Thus, the use of Geographic Information Systems (GIS) in epidemiology plays a crucial role in understanding the health-disease process. This allows for the strategic allocation of resources, the implementation of monitoring, and the adoption of 127

effective preventive and control measures for various parasitic diseases, including leishmaniasis (MARTINS-MELO et al., 2014b; SOUZA et al., 2018)

128

129 Therefore, the present study aims to know the epidemiological situation of VL and TL 130 co-infection with HIV, and to compare it with both when isolated in the state of Bahia. In 131 addition, we intend to map the geographic distribution of diseases in isolation and in co-132 infection, identify environmental, climatic and socioeconomic risk factors associated with these 133 cases, analyze and compare the epidemiological profile, including prevalence, lethality, 134 morbidity, age group, recurrences and treatment abandonment, and relate the occurrence of 135 isolated and concomitant infections to the municipalities of residence and notification.

136

#### 137 **Material and Methods**

138 This is an ecological time-series study, regarding cases of visceral leishmaniasis (VL), 139 tegumentary leishmaniasis (TL) and human immunodeficiency virus (HIV), isolated and in co-140 infection (VL/HIV and TL/HIV), of Bahia state in Brazil. That cases are obtained and analyzed 141 at the aggregate level, by municipality, from 2008 until 2022.

#### 142 1. Study area

143 The study was carried out in the state of Bahia, located in the Northeast Region of Brazil, 144 with an area of 564,760.429 km<sup>2</sup> and having the largest population in the Region, with 145 14,136,417 inhabitants. The 417 municipalities are grouped into nine Regional Health Center 146 (RHC), subdivided in Regional Health Bases (RHB), that are represented by specific 147 municipalities, considered as Health Operational Basis (HOB) (SESAB, 2023) (Figure 1).



**Figure 1.** Division of the Health Region and their Regional Health Centers, of Bahia state, in the Northeast Region of Brazil.

148

Legend 1. Regional Health Centers (RHC). I. Central-East, II. Center-North, III. Extreme South, IV. East, V. Northeast, VI. North, VII. West, VIII. Southwest, and IX. South.

149

#### 150 2. Data description

There was obtained human cases of VL and TL with and without co-infection with HIV, in addition to isolated cases of HIV, per year from 2008 to 2022. They were previously provided by the Health Department of the State of Bahia (SESAB) and available in the Notifiable Diseases Information System (SINAN).

The data VL and TL cases refer to the fillable fields of the investigation forms for each disease cases in SINAN, which is composed by sociodemographic (race/color, age group, sex, education, pregnant status and zone) and clinical-epidemiological questions (signs and symptoms, co-infection with HIV, type of diagnosis and case classification, type of treatment and the evolution of the case). There were also record the municipalities of residence, notification and probable location of infection (PLI). In case of PLI field is not filled in or ignored, the place of infection was considered to be the municipality of residence of the patients for the analyses, due to the chronic nature of the diseases, representing a higher probability of being infected in the site with the highest frequency.

Cases of HIV infection are composed by sociodemographic (age group, sex, race, and municipality of residence) and clinical-epidemiological questions (kind of transmission, such as sexual, through the use of drugs, blood transfusion, blood transfusion for hemophilia and accident with biological material, in addition to the type of diagnostic test and evolution of the case).

169 To calculate the incidence of cases, the population of each municipality was obtained 170 from the IBGE, available at the SINAN. They were specific of the census of 2010 and for the 171 other years they are estimated.

172

#### 173 **3.** Data analysis

174 *3.1 Descriptive analyzes* 

Descriptive analyzes were performed of all data, including their frequences were doneconsidering their confidence intervals (CI) of 95%.

177 *3.2 Statistical analyzes* 

To compare the symptoms of both diseases (TL, VL and HIV) and co-infection with HIV (TL/HIV and VL/HIV), there was performed chi-square and or Fisher's exact test, according to the data distribution. In order to identify the difference between the diseases isolated and in co-infection and their personal features (schooling, age group, pregnant woman, race/color, sex), zone of residence, treatment (Pentavalent Antimony, Amphotericin B, Liposomal Amphotericin B, Pentamidine, and other drugs) and diagnostic confirmation criteria (clinical forms, epidemiological classification, and case evolution), there was used the same
analyzes above, but followed by the post-hoc Chi-square test or Fisher's exact test (depending
on the data distribution), with Bonferroni correction. Both analyzes were done in R program
(version 4.2.3), with "rstatix" and "rcompanion" packages, considering a significance of 5% of
p-value (KASSAMBARA, 2023; MANGIAFICO, 2024; RSTUDIO TEAM, 2023).

189 There was considered the temporality of both incidence and lethality and for their 190 comparison, there was performed linear and Spearman's correlation, once the not normal 191 distribution after evaluation with Shapiro-Wilk test. Both analyses were performed using the 192 jamovi statistical software (version 2.3.21), considering a significance of 5%. Trend analysis 193 for temporally incidence (by year) was performed using a joinpoint regression model. That 194 model evaluates whether a line with multiple segments is statistically better at describing the 195 temporal evolution of a dataset compared to a straight line or a line with fewer segments. The 196 annual percentage change (APC) was calculated, considering a CI of 95% and significance of 197 5% for p-value. The following parameters were adopted: minimum of zero joinpoints and 198 maximum of two, Monte Carlo permutation test (4499 permutations), autocorrelation of errors 199 based on the data, and constant variance. When there is no inflection in the analysis, the trend 200 is represented by a single straight line. The results were interpreted as follows: positive 201 significant APCs were considered as increasing trends, negative significant APCs as decreasing 202 trends and with no significance as stationary. These analyzes were performed in Joinpoint 203 Regression program (version 5.2.0.1) and R, with car package and function ncvTest, to evaluate 204 the variance of data (NCI, 2023).

It is noteworthy that for the analysis of TL isolated and TL/HIV co-infection, it was not possible to compare the variables as a function of the medications due to the lack of specific information in the database.

208 *3.3 Spatial analyzes* 

209

210

211

The spatial distribution was performed using thematic maps of the incidence of both diseases, performed in the QGIS software (version 2.18).

In order to identify areas of hot and cold spots, there were performed spatial

212 autocorrelation of the incidence of VL, TL, HIV, and VL/HIV and TL/HIV, per municipality, 213 by using Moran's analysis, including Local Moran (LISA) and global (IMG) indices. In addition 214 there was performed Moran's bivariate correlation between these diseases and variables human 215 development (Municipal Human Development Index - HDI), education (illiteracy rate), 216 housing (frequency of the urban population living in households connected to the water supply 217 network and frequency of the urban population served by regular household waste collection 218 services), work (frequency of those employed in the agricultural and mineral extraction sectors), 219 environment (average rainfall, temperature and humidity), income (Gross Domestic Product -220 GDP, Gini index, unemployment rate, frequency of poor, vulnerable to poverty and extremely 221 poor, frequency of people registered with CadÚnico or beneficiaries of Bolsa Família). For 222 these analyzes, the neighborhood matrix was defined considering the inverse of the distance 223 between the centroids of the municipalities, which defines that closer neighbors have greater 224 influence than more distant neighbors. A minimum distance of 91.20 km was defined, so that 225 all municipalities had at least one neighbor. In order to test de randomness of results and the 226 significance of the test statistics, the analyzes were tested through 999 randomizations 227 (empirical pseudosignificance) in order to obtain the. The analyses were performed using the 228 GeoDa 1.22.0.2 software, and the significance of 5% for p-value was considered.

229

230 *4. Ethical Aspects* 

The study was authorized by SESAB and received ethical approval from the Research
Ethics Committee of the State University of Santa Cruz, registered with opinion no. 4.784.218
(CAAE 47443721.4.0000.5526).

234

| 235 | Results  |
|-----|--|
| 236 | VL and VL/HIV coinfection  |
| 237 | From 2008 to 2022, 8,664 cases of VL were reported, of which 57.18% (4,954) were                 |
| 238 | confirmed, 2.30% (114; 95% CI: 1.88%-2.72%) of them as VL/HIV coinfection. Of the                |
| 239 | VL/HIV cases, the majority, 83.33% (95; 95% CI: 76.49%–90.17%) had the entry type as new         |
| 240 | cases, rather than recurrence, transfer, or ignored, and this information was not present for    |
| 241 | isolated VL cases. The other 42.8% (3,710) registered VL cases were not confirmed because a      |
| 242 | change in diagnosis to other diseases, a negative result in the confirmatory test, or the period |
| 243 | for confirmation had not ended until the present study were noted on the notification form.      |
| 244 | (Figure 2).  |

Figure 2. Number and frequency of reported cases of VL isolated and in co-infection with HIV, 245 246 according to the type of entry and confirmatory status.



247

248 Regarding temporality, VL cases remained constant from 2008 to 2013 (mean: 1.72 per 249 100,000 inhabitants; standard deviation: 1.81), with a notable increase in 2014 (Jan-Apr: 113; 250 May-Aug: 102; Sept-Dec: 94 cases), reduction in 2016 and subsequent decline in the following 251 years, until 16 cases in Sep-Dec 2022 (Figure 3). On the other hand, the proportion of VL/HIV



Figure 3. Number of total VL cases and proportion of VL/HIV co-infection within VL isolated,
by four -month period and year of first symptoms.





The Joinpoint regression analysis showed an increase of the incidence of VL (slope = 0,13), from 2007 until 2014, with a broke to downward trend in the period from 2014 to 2022, reducing annually an average of 26% (*average annual percent change* (AAPC) = -26%; slope: -0.26; CI 95%: -0.32 to -0.20; p-Value: 0.002), corroborating with decreasing of cases. No significant data were found on the trend of VL/HIV co-infection, and it was considered stationary and stable (APC: 0.02; CI 95%: -0.01 to 0.05; p-Value: 0.454) (**Figure 4**).

# Figure 4. Trend of the Joinpoint regression coefficient of the incidence of VL and in VL/HIV co-infection in Bahia, 2008-2022.



**Multiple Joinpoint Models** 

269

270 When analyzing the age pyramid of new cases, it is observed that VL isolated and 271 VL/HIV co-infection have most cases in males (61.87%; 2737 and 73.27%; 74; respectively), 272 but different distribution according to age group. For isolated VL, in males they are more 273 frequent in groups from 1 to 4 (624), from 20 to 34 (525) and from 35 to 49 years (396), and in females (1687), the cases are most frequent in groups from 1 to 4 (n=626) and from 5 to 9 years 274 275 (Figure 7). Regarding VL/HIV co-infection, most cases are concentrated in males in groups 276 from 35 to 49 years (35), from 20 to 34 (19) and from 50 to 64 years (11), and in females (n=27), 277 the high distribution of new cases is in groups of 35 to 49 (7), from 20 to 34 years (4) from 15 278 to 19 and from 5 to 9 years (both with 4) (Figure 5).

Figure 5. Age pyramid of new cases of VL and VL/HIV co-infection, according to sex, between 280 2007 and 2022, in Bahia, Brazil.



281

282 Related to clinical signs and symptoms of all cases (new, recurrence and hospital 283 transference), the prevalence of fever was significantly (X<sup>2</sup>: 5.760; p-Value: 0.016) higher 284 (90.0%) with VL isolated than with VL/HIV co-infection (83.2%) (Figure 6). The presence of edema was significantly (X<sup>2</sup>: 5.437; p-Value: 0.020) higher in VL cases (30.4%) than in 285 286 VL/HIV co-infection (20.3%). For the other clinical signs and symptoms as weakness, weight 287 loss, cough and/or diarrhea, pallor, spleen enlargement, infectious condition, hemorrhagic 288 phenomena, liver enlargement, jaundice there were no difference at their frequences between 289 cases of VL and VL/HIV co-infection.





292

293 Most patients with isolated VL had completed high school (33.0%; 515/1561), with 294 VL/HIV had completed elementary school (29.8%; 14/47) and with isolated HIV had 295 completed elementary school (36.6%; 6244/17053) (Figure 7A). Significant differences in 296 education pattern, regarding the distribution and proportion of categories, were found only 297 between the groups with isolated HIV and VL/HIV coinfection and isolated VL (both with 298 p<0.001). However, the proportions of illiterate individuals with complete elementary school 299 and with incomplete high school were not statistically different among the three infected groups 300 (p=0.861 and p=0.191, respectively). The field of education was ignored in 64.4% (2820), 301 50.5% (48) and 36.6% (9835) of the cases of VL, VL/HIV and HIV, respectively, thus they 302 were not included at calculation of frequences.

Analyzing the data for the age group, the patients with both HIV and VL/HIV coinfection were mostly adults (88% and 73.7% respectively), however the percentage of child was higher (12,6%) in VL/HIV than HIV (1.3%), being significant differently the patterns of age group frequences between the VL and other both groups (HIV and VL/HIV; p<0.001 for both). On the other hand for VL isolated the major cases were child (46.5%; 2,015) and with higher frequence of adolescents (14.0%) than the other cases with a statistical different pattern
- 309 between them (p<0.001) (**Figure 7B**). However, the absence of a significant difference between
- 310 adolescents and the old (p=0.775) suggests a similarity between these two groups in the context
- 311 analyzed.
- 312

- **Figure 7.** Characteristics associated with schooling (A) and age group (B) to the occurrence of
- 314 VL/HIV, VL isolate, and HIV isolate co-infection from 2008 to 2022 in the state of Bahia.



In the group with isolated VL, 96.3% (422) of patients were not pregnant. Among those with VL/HIV coinfection, 92.9% (13) were not pregnant. In contrast, in the HIV isolated group, 56.1% (5,968) of patients were pregnant, and 43.9% (4,678) were not. Significant differences were observed between VL/HIV and HIV isolated groups, as well as between VL isolated and HIV isolated groups (p<0.001), highlighting a higher prevalence of pregnant women in the HIV group. Additionally, comparisons between pregnant and non-pregnant women across groups showed a significant difference (p<0.001).

323 In the group with isolated VL, most patients were brown (70.9%; 2,806), followed by 324 black (17.2%; 681). Among those with VL/HIV coinfection, 72.3% (60) were brown, and 325 16.9% (14) were black. In the HIV isolated group, brown patients also predominated (60.8%; 326 14,103), while 26.7% (6,189) were black (Figure 8). Significant differences in race/color were 327 observed only between the isolated VL and isolated HIV groups (p<0.001). Additionally, 328 significant differences were found among race/color categories, including yellow vs. 329 indigenous (p=0.003), yellow vs. black, white vs. brown (p=0.001), and white vs. black, and 330 brown vs. black (p<0.001). However, no significant differences were observed between yellow 331 and white (p=0.169) or between indigenous and black (p=0.554).

**Figure 8.** Number and frequence of race/color of patients with of VL/HIV, VL isolate, and HIV

isolate co-infection, from 2008 to 2022 in the state of Bahia.



334

Men were more frequently affected by both diseases, being 61.9% (2,709), 72.6% (1,670) and 53.1% (14,260), of them infected with VL, VL/HIV and HIV, respectively. Significant differences were observed between all couple of group cases, such as VL/HIV and VL (p=0.032), VL and HIV (p<0.001) and VL/HIV and HIV (p<0.001), indicating a higher prevalence of men in the VL and VL/HIV groups, while patients with HIV had a more balanced gender distribution.

Related to the residence, for VL and VL/HIV 1.1% (47 and 1, respectively) of cases lived in peri-urban area. Among the other areas (urban and rural), the most frequence of cases lived in urban, mostly for VL/HIV (79.6%; 74), and significantly higher (p<0.001) than for VL (52.4%; 2,228). Comparisons between rural and urban areas also showed significant differences (p<0.001). However, no significant differences were found between peri-urban and rural areas (p=0.546) or between peri-urban and urban areas (p=1.000). 347 Regarding patients treated with drugs, Pentavalent Antimony was the most frequently 348 used for both diseases, but more frequently for VL (79.77%; 3,395/4,256) than for VL/HIV 349 (52.0%; 51/98). Amphotericin B was the other most frequently used drug, but liposomal drugs 350 were more frequently used than non-liposomal drugs for both diseases treated. Pentamidic 351 drugs were administered exclusively for VL, but in less than 1% of cases. For VL, "other drugs" 352 were also used in 7.24% of cases, and are commonly used as secondary treatment, since the 353 elective drug is not effective or the patient cannot receive it. No drug was used in 2.84% (9) 354 and in 97.16% (308) of the VL/HIV and VL cases, but it was not possible to identify their 355 evolution (death or not) in the data record (Table 1).

356 The most frequent cases recorded were new cases, with 96.18% (4,381) and 86.36% of 357 VL and VL/HIV, respectively. Recurrence was higher for VL/HIV (13.64%; 15) than for VL 358 (3.82%; 174) and notifications marked as transfer and ignored were rare for both diseases. The 359 most used diagnoses among positive cases of VL/HIV and VL were clinical-epidemiological 360 (6.40% and 8.02%, respectively) and parasitological (5.23% for VL/HIV) and IFAT (5.66% for 361 VL), reinforcing the relevance of laboratory confirmation and clinical-epidemiological 362 evaluation in the detection of the disease. Among the negative results, clinical-epidemiological 363 ones stand out (6.69% for VL/HIV and 8.02% for VL), indicating the importance of the clinical 364 approach to exclude suspected cases.

Regarding the evolution of cases, cure was achieved in 10.81% (428) of VL cases and 10.84% (9) in VL/HIV co-infection. Deaths from other causes occurred in 70.88% (2,806) of VL cases and 72.29% (60) in co-infection. Deaths directly due to VL and cases of abandonment were observed exclusively in VL cases, with frequencies of 0.28% and 0.83% (11 and 33, respectively) (**Table 1**).

- 370 Table 1. Characteristics of initial drug administered, type of entry, types of diagnosis, and evolution in VL/HIV and VL coinfection from 2008 to 371 2022 in the State of Bahia.
  - **Coinfection VL/HIV** VL Characteristic Freq (%) **CI 95%** Freq (%) **CI 95%** N N Amphotericin B 20 20.41 (12.43 - 28.39)249 5.85 (5.15 - 6.56)Liposomal Amphotericin B 27 27.55 (18.71 - 36.40)281 6.60 (5.86 - 7.35)Pentavalent Antimony 51 52.04 (42.15 - 61.93) 79.77 (78.56 - 80.98)3395 Pentamidine 0.00 23 0.54 (0.32 - 0.76)Initial Drug Administered 0 308 (6.46 - 8.02)Other 0 0.00 7.24 Not used\* 308 9 \_ \_ \_ Ignored\* 7 380 Total 98 4256 (95.62 - 96.74) New case 95 86.36 (79.95 - 92.78)4381 96.18 15 3.82 Relapse 13.64 (7.22 - 20.05)174 (3.26 - 4.38)Input Type Transfer\* 2 125 \_ 2 Ignored\* 122 **Total** 110 4555 Positive - Parasitological, IFAT and 2 0.58 (0.00 - 1.38)54 0.35 (0.25 - 0.44)Others Positive - Parasitological and IFAT 12 3.49 (1.55 - 5.43)326 2.10 (1.87 - 2.32)Positive - Parasitological and Others 11 3.20 (1.34 - 5.06)223 1.43 (1.25 - 1.62)Types of Diagnosis Positive - IFAT and Others 2.91 355 2.28 10 (1.13 - 4.68)(2.05 - 2.52)Positive - Parasitological 18 5.23 (2.88 - 7.59)445 2.86 (2.60 - 3.12)13 3.78 881 (5.30 - 6.03)Positivo - IFAT (1.76 - 5.79)5.66 Positive - Other 3.78 (1.76 - 5.79)756 4.86 (4.52 - 5.20)13

|           | Positive - Clinical-Epidemiological | 22  | 6.40  | (3.81 - 8.98)   | 1247  | 8.02  | (7.59 - 8.44)   |
|-----------|-------------------------------------|-----|-------|-----------------|-------|-------|-----------------|
|           | Negative - Parasitological          | 12  | 3.49  | (1.55 - 5.43)   | 370   | 2.38  | (2.14 - 2.62)   |
|           | Negative - IFAT                     | 11  | 3.20  | (1.34 - 5.06)   | 401   | 2.58  | (2.33 - 2.83)   |
|           | Negative - Other                    | 14  | 4.07  | (1.98 - 6.16)   | 447   | 2.87  | (2.61 - 3.14)   |
|           | Negative - Clinical-Epidemiological | 23  | 6.69  | (4.05 - 9.33)   | 1248  | 8.02  | (7.60 - 8.45)   |
|           | Not performed - Parasitological     | 59  | 17.15 | (13.17 - 21.13) | 3406  | 21.89 | (21.24 - 22.54) |
|           | Not realized - IFAT                 | 62  | 18.02 | (13.96 - 22.09) | 2576  | 16.56 | (15.97 - 17.14) |
|           | Not performed - Other               | 62  | 18.02 | (13.96 - 22.09) | 2822  | 18.14 | (17.53 - 18.75) |
|           | Total                               | 344 |       |                 | 15557 |       |                 |
|           |                                     |     |       |                 |       |       |                 |
|           | Abandonment                         | 0   | 0.00  | -               | 33    | 0.83  | (0.55 - 1.12)   |
|           | Cure                                | 9   | 10.84 | (4.15 - 17.53)  | 428   | 10.81 | (9.84 - 11.78)  |
| Evolution | Death from VL                       | 0   | 0.00  | -               | 11    | 0.28  | (0.11 - 0.44)   |
| Evolution | Death from other causes             | 60  | 72.29 | (62.66 - 81.92) | 2806  | 70.88 | (69.46 - 72.29) |
|           | Transfer                            | 14  | 16.87 | (8.81 - 24.92)  | 681   | 17.20 | (16.03 - 18.38) |
|           | Ignored*                            | 12  | -     | -               | 422   | -     | -               |
|           | Total                               | 83  |       |                 | 3959  |       |                 |

**Legend 2.** \*Not considered for frequency analysis; CI - Confidence Interval; IFAT - Indirect Fluorescent Antibody Test

Among new cases and recidivism, the main treatment was with antimonial pentavalent, however it was higher for new cases (80.87% and 66.44%, respectively) (**Table 2**). The patients with recidivism receive more amphotericin B liposomal and no liposomal (17.45% and 9.40%, respectively) than new cases (6.18% and 5.0%, respectively). Pentamidine was used most for new cases (21) and for transferred (2) cases. However, it is important to cite that transferred is not necessarily a severe case of the disease, it be a more accessible service for treatment.

The deaths of VL occurred mostly when using amphotericin B and amphotericin B Liposomal (15.4% for both), compared with the cure (4.7% and 5.7%, respectively) and deaths by other causes (12.7% and 12.7%, respectively) (**Table 2**). The Pentamidine was used mostly in cured cases (19) and just one death by VL. Other drugs for the treatment were used mostly in deaths by other causes (10.91%), perhaps because they are target to secondary choose or support for other complications. There was not abandoned of treatment when using Amphotericin B Liposomal.

For VL/HIV the new cases were more treated with antimonial pentavalent (59.04%) and the recidivism were treated most with amphotericin B liposomal (53.85%) followed by that amphotericin B (38.46%), such as the pattern of treatment of VL isolated. Regarding the deaths from VL the most of them was treated with antimonial pentavalent (66.67%), followed by amphotericin B (33.33%). There was no cases treated with amphotericin B liposomal that resulted in death by VL, however this drug was used in high percentage of cases that died from other causes.

Adolescent, child rand adult received more antimonial pentavalent for treat VL/HIV than older patients, which received more amphotericin B liposomal (23.65%) than that not liposomal (13.30%). No significant associations were found between confirmation criteria, evolution, or age group and type of drug (p=0.382, p=1.000, p=0.246, p=0.266, p=0.297, and p=0.089, respectively) (**Table 3**).

| Characteristic |                         | Amphotericin<br>B |       | Amphotericin<br>B Lipossomal |       | Antimonial<br>Pentavalent |       | Pentamidine |      | Other |       | Total |
|----------------|-------------------------|-------------------|-------|------------------------------|-------|---------------------------|-------|-------------|------|-------|-------|-------|
|                |                         | Ν                 | %     | Ν                            | %     | Ν                         | %     | Ν           | %    | Ν     | %     | -     |
|                | New case                | 216               | 5.50  | 243                          | 6.18  | 3178                      | 80.87 | 21          | 0.53 | 272   | 6.92  | 3930  |
| Casa Tura      | Recidivism              | 14                | 9.40  | 26                           | 17.45 | 99                        | 66.44 | 0           | 0.00 | 10    | 6.71  | 149   |
| Case Type      | Transfer*               | 12                | 11.01 | 9                            | 8.26  | 74                        | 67.89 | 2           | 1.83 | 12    | 11.01 | 109   |
|                | Ignored*                | 7                 | 10.29 | 3                            | 4.41  | 44                        | 64.71 | 0           | 0.00 | 14    | 20.59 | 68    |
|                |                         |                   |       |                              |       |                           |       |             |      |       |       |       |
|                | Abandonment             | 2                 | 8.33  | 0                            | 0.00  | 20                        | 83.33 | 0           | 0.00 | 2     | 8.33  | 24    |
|                | Care                    | 148               | 4.67  | 180                          | 5.69  | 2615                      | 82.60 | 19          | 0.60 | 204   | 6.44  | 3166  |
|                | Death from VL           | 34                | 15.04 | 34                           | 15.04 | 144                       | 63.72 | 1           | 0.44 | 13    | 5.75  | 226   |
| Evolution      | Death from other causes | 7                 | 12.73 | 7                            | 12.73 | 35                        | 63.64 | 0           | 0.00 | 6     | 10.91 | 55    |
|                | Transfer*               | 19                | 7.66  | 19                           | 7.66  | 191                       | 77.02 | 0           | 0.00 | 19    | 7.66  | 248   |
|                | Ignored*                | 39                | 7.29  | 39                           | 7.29  | 390                       | 72.90 | 3           | 0.56 | 64    | 11.96 | 535   |
|                |                         |                   |       |                              |       |                           |       |             |      |       |       |       |
|                | Child                   | 109               | 5.46  | 124                          | 6.21  | 1634                      | 81.78 | 13          | 0.65 | 118   | 5.91  | 1998  |
|                | Adolescent              | 31                | 5.16  | 20                           | 3.33  | 514                       | 85.52 | 3           | 0.50 | 33    | 5.49  | 601   |
| Age group      | Adult                   | 81                | 5.85  | 86                           | 6.21  | 1088                      | 78.61 | 6           | 0.43 | 123   | 8.89  | 1384  |
|                | Old                     | 27                | 11.74 | 48                           | 20.87 | 128                       | 55.65 | 1           | 0.43 | 26    | 11.30 | 230   |
|                | Ignored*                | 1                 | 2.33  | 3                            | 6.98  | 31                        | 72.09 | 0           | 0.00 | 8     | 18.60 | 43    |

**Table 2.** Comparison of the initial drug administered with associated characteristics in VL isolated from 2008 to 2022 in the State of Bahia.

399 Legend 3. \*Data not considered for chi-square analysis; Data not considered for chi-square analysis. IFAT - Immunofluorescent Antibody Test.

| 403 | Table 3. Comparison of the initial drug administered with associated characteristics in VL/HIV co-infection from 2008 to 2022 in the State of |
|-----|---|
| 404 | Bahia.  |

| Characteristic |                         | Amph | otericin B | Amph<br>Lipe | otericin B<br>ossomal | Antimonial<br>Pentavalent |       | Total |
|----------------|-------------------------|------|------------|--------------|-----------------------|---------------------------|-------|-------|
|                | -                       |      |            | Ν            | %                     | Ν                         | %     | -     |
|                | New case                | 15   | 18.07      | 19           | 22.89                 | 49                        | 59.04 | 83    |
| Case Type      | Recidivism              | 5    | 38.46      | 7            | 53.85                 | 1                         | 7.69  | 13    |
|                | Transfer*               | 0    | -          | 1            | 50.00                 | 1                         | 50.00 | 2     |
|                |                         |      |            |              |                       |                           |       |       |
|                | Care                    | 14   | 22.58      | 14           | 22.58                 | 34                        | 54.84 | 62    |
|                | Death from VL           | 1    | 33.33      | 0            | 0.00                  | 2                         | 66.67 | 3     |
| Evolution      | Death from other causes | 1    | 14.29      | 4            | 57.14                 | 2                         | 28.57 | 7     |
|                | Transfer                | 2    | 22.22      | 3            | 33.33                 | 4                         | 33.33 | 9     |
|                | Ignored*                | 2    | -          | 6            | 35.29                 | 9                         | 52.94 | 17    |
|                |                         |      |            |              |                       |                           |       |       |
|                | Child                   | 109  | 5.84       | 124          | 6.64                  | 1634                      | 87.52 | 1867  |
|                | Adolescent              | 31   | 5.49       | 20           | 3.54                  | 514                       | 90.97 | 565   |
| Age group      | Adult                   | 81   | 6.45       | 86           | 6.85                  | 1088                      | 86.69 | 1255  |
|                | Old                     | 27   | 13.30      | 48           | 23.65                 | 128                       | 63.05 | 203   |
|                | Ignored*                | 1    | 2.86       | 3            | 8.57                  | 31                        | 88.57 | 35    |

**Legend 4.** \*Data not considered for chi-square analysis; Data not considered for chi-square analysis. IFAT - Immunofluorescent Antibody Test.

406 During the period studied, the overall mortality coefficient for VL was higher than for 407 VL/HIV (2.19, and 0.04 per 100 thousand inhabitants, respectively). The VL/HIV deaths 408 occurred in Municipalities of América Dourada, Juazeiro, Salvador, São Francisco do Conde 409 and Xique-Xique, both cities with one death each, located in the central-east, east, central-north 410 and north health regions. In addition, among these deaths, 100% (n=5) of the victims had more 411 than three VL symptoms, mainly severe symptoms, such as hemorrhagic phenomena (n=01/05)412 and liver enlargement (n=02/05). Regarding sociodemographic characteristics, 60% (n=03/05) 413 of the deaths were male and of brown race/color, and 100% (n=05) of the victims only had 414 incomplete elementary school.

415 The lethality rate of VL has increased over the years, with its highest rate in 2021 416 (13.33%), and the lethality of AIDS has been a decreasing, thus the correlation of them was 417 significant and inverse (rho=-0.729, p=0.003, R<sup>2</sup>=0.287). In the case of VL/HIV, there were 418 observed oscillation at lethality rate through the period, including zero cases in some years, 419 however it is important to know that the number of cases of co-infection was also low in that 420 period (maximum of 15). There was no significant correlation between lethality of VL/HIV co-421 infection and of AIDS (rho=-0.270, p=0.330, R<sup>2</sup>= 0.000997) and of VL (rho=-0.190, p=0.270, 422 R<sup>2</sup>= 0.000865) (Figure 9).



## Figure 9. Annual lethality rate of cases of VL, VL/HIV and AIDS in the state of Bahia, between 2008 and 2022.

The incidence of VL, HIV, and VL/HIV co-infection showed a distinct pattern of geographical distribution in the state, in which VL cases were more prevalent in the central and western areas, while HIV cases were clustered in the coastal and extreme southern regions and otherwise, the cases of VL/HIV co-infection are distributed spread throughout the state, excluding the south and extreme south sites (**Figure 10**).



Figure 10. Spatial distribution of incidences of cases VL, HIV and VL/HIV co-infection by
municipality in Bahia from 2008 to 2022.

433

The Moran's Global autocorrelation index (IMG) for the incidences was higher for HIV
(0.581; sd = 0.0286), showing higher clusters of cases or absence of cases, followed by of VL
(0.445; sd = 0.0296), and VL/HIV (0.108; sd = 0.0286).

Regarding the incidence of VL, significant areas of spatial dependence were observed,
as well as low or zero incidence in 25.42% (106/417) at the municipalities in the southern and
extreme southern macro-regions (in dark blue "Low-Low" at Figure 11) and high concentration
of cases in 9.35% (39) of the municipalities located in the central-eastern and central-northern
macro-regions (in dark red "High-High" at Figure 11).

There were observed high concentration in the neighboring municipality in 6% (25) of the municipalities dispersed in all regions of the state (light blue "Low-High") and high concentration of cases in 2.64% (11) of the municipalities, located in the southwest and centraleastern macro-regions, highlighted in dark red "High-High" (**Figure 11**). The incidence of isolated HIV cases, significant areas of spatial dependence were observed, as well as low or no incidence in 18.94% (79) of the municipalities in the southwest and west macro-regions (dark blue "Low-Low"), in addition to the high concentration of cases in 9.83% (41) of the municipalities, located in the south and far-south macro-regions, highlighted in dark red "High-High" (**Figure 11**).

In addition, regarding the incidence of isolated HIV cases, significant areas of spatial dependence were observed, as well as low or no incidence in 18.94% (79) of the municipalities in the southwest and west macro-regions (dark blue "Low-Low"), in addition to the high concentration of cases in 9.83% (41) of the municipalities, located in the south and far-south macro-regions, highlighted in dark red "High-High" (**Figure 11**).

456 Figure 11. Moran's local indices of incidence of VL, HIV and VL/HIV cases (mean between
457 2008 and 2022), by municipality in Bahia state, Brazil.



459 Legend 5. The numbers in brackets represent the numbers of municipalities in each category.

460

458

| 461 | The incidence of VL/HIV had a positive (direct) spatial correlation with the incidence               |
|-----|--|
| 462 | of VL isolated (IMG: $0.213$ ; sd = $0.0243$ ). Moran's local bivariate analysis also indicated that |
| 463 | the major municipality with significant correlation (39.85%; 104) are in the northern, southern      |
| 464 | and extreme southern areas of the state, presenting low incidence of VL/HIV coinfection and          |
| 465 | of VL isolated ("low-low" pattern; dark blue at Figure 12A). On the other hand, for the              |
| 466 | incidences of VL/HIV and HIV presented negative (inverse) correlation (IMG: -0.073; sd =             |
| 467 | 0.0212), in which there is of low coinfection and high incidence of HIV ("low-high" pattern)         |
| 468 | in 13.59% (39) of the municipalities in the southwest and west areas of the state. For the           |
| 469 | incidences of VL and HIV, there is also a negative (inverse) spatial correlation (IMG: -0.201;       |
| 470 | sd = $0.0216$ ), with 15.33% (44) of the municipalities in the southwest and west areas of the state |
| 471 | presenting low of VL and high of HIV ("low-hight" pattern) (Figure 12).                              |

472 Figure 12. Local bivariate spatial correlation of the incidences of: A – VL/HIV coinfection and
473 VL isolated; B - VL/HIV and HIV coinfection isolated; C - VL isolated and HIV isolated in the
474 state of Bahia, Brazil, 2008-2022.





Index (IMG: 0.043; sd = 0.0212), access to piped water (IMG: 0.017; sd = 0.0206), and employment in the agricultural sector (IMG: 0.063; sd = 0.0211). In contrast, a negative correlation was found for the illiteracy rate (IMG: -0.098; sd = 0.0216), urban household waste collection (IMG: -0.066; sd = 0.021), and employment in the mining sector (IMG: -0.007; sd = 0.0215) (**Figure 13**).

483 A lower incidence of VL/HIV co-infection was associated with low MHDI (15.36%; 47/417), high illiteracy rates (13.29%; 55/417), and extensive waste collection coverage 484 485 (12.24%; 42/417), with spatial patterns distributed mainly in the eastern, western, southwestern, 486 and extreme southern regions. Conversely, a higher incidence of VL/HIV co-infection was 487 observed in municipalities with greater agricultural employment (3.47%; 11/417), 488 predominantly in the north and southwest, and in areas with better access to piped water (3.95%; 489 12/417), primarily in the eastern and northern regions (Figure 13). 490 Additionally, regions with significant mining employment (6.70%; 24/417) exhibited a 491 negative correlation, indicating a lower incidence of the disease. (Figure 13).

492 Figure 13. Local bivariate spatial correlation of the incidence of VL/HIV co-infection with: A
493 – Municipal Human Development Index (MHDI); B – Illiteracy rate; C – Percentage of the
494 urban population residing in households connected to the water supply network; D – Percentage
495 of the urban population served by regular household waste collection services; E – Percentage

of those employed in the agricultural sector; F – Percentage of those employed in the mineral
 extractive sector, in the state of Bahia, period 2008-2022.



499 Continuing, the average rainfall (A) showed a negative correlation (IMG: -0.062; sd = 500 0.0207), with a predominance of low-low patterns in 47.55% (97) of the municipalities, 501 concentrated in the north and southwest regions. Regarding the mean temperature (B), a 502 positive association was identified (IMG: 0.060; sd = 0.0209). The high-high clusters 503 corresponded to 12.33% (27) of the municipalities, located in the central-north, north and west 504 areas, highlighted in red. These results suggest the existence of a direct influence, in which the 505 higher the incidence of VL/HIV co-infection, the higher the temperature. The mean moisture 506 content (C) exhibited a strong negative correlation (IMG: -0.155; sd = 0.0216). In this context, 507 low-high patterns prevailed in 56.63% (111) of the municipalities, distributed in the eastern, southern and extreme southern regions of the state. These results highlight areas that indicate 508 509 low incidence of the disease and high humidity (Figure 14).

498

| 510 | In the case of Gross Domestic Product (GDP) (D), a direct (positive) correlation was             |
|-----|--|
| 511 | identified (IMG: $0.055$ ; sd = $0.0218$ ). High-high clusters represented 2.20% (8) of the      |
| 512 | municipalities, indicating an association between higher incidence of the disease and locations  |
| 513 | with greater economic prosperity. Nevertheless, for the Gini Index (E), a direct correlation was |
| 514 | detected (IMG: 0.056; sd = 0.0215). High-high patterns were identified in 1.54% (n=5) of the     |
| 515 | areas, distributed in the central and northern regions of the state. Even so, the unemployment   |
| 516 | rate (F) showed an inverse association (IMG: $-0.015$ ; sd = $0.0211$ ). In this sense, low-high |
| 517 | clusters predominated in 8.41% (29) of the municipalities, distributed among the eastern,        |
| 518 | southwestern, and southern regions of the state of Bahia (Figure 14).                            |

Figure 14. Local bivariate spatial correlation of the incidence of VL/HIV co-infection with: A
Mean Rainfall; B – Average Temperature; C – Average Humidity; D – Gross Domestic
Product (GDP); E – Gini Index; F – Unemployment Rate, in the state of Bahia, period 20082022.



523 524

Consequently, socioeconomic variables related to poverty and access to social programs

526 0.059; sd = 0.0214), with 5.30% (15) of the municipalities having high-high clusters, widely 527 distributed in areas of the central-north and west regions, indicating a high incidence of the 528 disease and a high poverty rate. The proportion of people vulnerable to poverty (B) also 529 revealed a direct correlation (IMG: 0.042; sd = 0.0213). In this context, high-high patterns 530 prevailed in 3.24% (10) of the municipalities, also highlighting the same regions, central-north 531 and west (**Figure 15**).

532 When the percentage of extremely poor people (C) was analyzed, a positive (direct) 533 association was found (IMG: 0.079; sd = 0.0213). Low-low patterns were predominant in 534 28.52% (75) of the localities, while high-high clusters were concentrated in 6.46% (17) of the 535 municipalities, revealing areas in which both variables have a direct relationship. Finally, the proportion of people enrolled in CadÚnico or beneficiaries of Bolsa Família (D) showed a direct 536 537 correlation (IMG: 0.055; sd = 0.0214). High-high clusters appeared in 4.17% (13) of the 538 localities, while low-low patterns were recorded in 14.10% (44) of the municipalities (Figure 539 15).

These results reinforce the existence of a significant relationship between the variables analyzed. It is observed that the increase in the incidence of VL/HIV co-infection is associated with a higher proportion of people benefiting from social programs or in conditions of poverty. Conversely, the reduction in cases of co-infection corresponds to a lower proportion of those enrolled in these programs or with higher income.

Figure 15. Local bivariate spatial correlation of the incidence of VL/HIV co-infection with: A
 Percentage of Poor; B – Percentage of Vulnerable to Poverty; C – Percentage of Extremely



547 Poor; D – Percentage of people enrolled in CadÚnico or beneficiaries of Bolsa Família, in the
 548 state of Bahia, period 2008-2022.



550

551 TL and TL/HIV coinfection

Also in the period from 2008 to 2022, 41,303 cases of LT were reported, of which 98.40% (40,644/41,303) were confirmed for the disease, 0.48% (195/40,644; 95% CI: 0.41% -0.55%) of them as LT/HIV coinfection, and 86.15% (168/195; 95% CI: 81.31% - 91.00%) of the coinfected cases classified as new cases. The other 659 (1.6%) of LT were not confirmed

- 556 because there was a change in diagnosis, a negative result in the confirmatory test or the
- 557 deadline for confirmation had not ended (Figure 16).
- **Figure 16.** Description of the number of reports and frequency of cases of TL isolated and in co-infection with HIV, according to the type of entry and confirmatory status.



560

561 In relation to TL, the temporality of the cases shows an increase in the number of cases, 562 with a considerable increase in 2010 (Jan-Apr: 1848), 2011 (Jan-Apr: 1463) and 2012 (May-563 Aug: 1658) and a decrease after that (mean: 2.98; standard deviation: 3.72). When analyzing the proportion of cases of TL/HIV co-infection, the four-month period from January to April 564 565 2010 stands out, with 1.24% (23/1848; CI 95%: 0.74% - 1.75%), with the highest proportions 566 of TL/HIV co-infection (Figure 17). Although few numbers of cases were recorded in May to 567 August 2019and 2020, they represented 0.87% TL/HIV co-infection (2/230; CI 95%: -0.33% -2.07% and /231; CI 95%: -0.33% – 2.06%, respectively). No significant correlation was found 568 569 between the number of total TL cases and the proportion of TL/HIV co-infection cases, in Spearman's correlation analysis, (rho= -0.088, p=0.563, R<sup>2</sup>=0.005). 570





In the case of TL, the Joinpoint regression analysis showed an increase of cases (slope: 3.04) until 2010, with significant broke to downward trend in the period until 2014 (slope: -5.23; CI 95%: -1.51 - 0.18; p-Value: 0.012), and with other broke turning to slope: -1.17 in the subsequent period. Regarding TL/HIV co-infection, there is also a similar pattern, increasing until 2010 (slope: 0.05), with significant broke to downward trend in the period from 2010 to 2013 (slope: -0.06; CI 95%: -0.08 - -0.04; p-Value: 0.025), and followed by another broke with a slope of 0.00, representing establishment of cases during the period (**Figure 18**).

Figure 18. Trend of the Joinpoint regression coefficient of the incidence of TL and in TL/HIV
 co-infection in Bahia, 2008-2022.



**Multiple Joinpoint Models** 

583

584 The age pyramid of new cases of isolated TL and TL/HIV co-infection also shows 585 different distribution according to age group and most frequence in males (22,588 and 109; 586 respectively). For isolated TL the cases in males are more frequent in groups from 20 to 34 587 (6030), from 35 to 49 (4,203) and from 50 to 64 years (946). In females (15,203), cases also occur in greater numbers in the age groups of 20 to 34 years (3,782), 35 to 49 years (2,739) and 588 589 50 to 64 years (1,924), respectively (Figure 8). In cases of TL/HIV co-infection, the most 590 frequence in males is in groups from 35 to 49 (33), from 20 to 34 (29) and from 50 to 64 years 591 (6), being the age groups with the highest number of cases, respectively. For females, the 592 distribution of new cases is mostly in the groups from 20 to 34 years (11), from 35 to 49 years 593 (10) and from 10 to 14 years (9), respectively (Figure 19).

Figure 19. Age pyramid of new cases of TL and TL/HIV co-infection, according to sex,
between 2007 and 2022, in Bahia, Brazil.



596

Regarding the clinical data of TL and TL/HIV co-infection, significant results were
observed regarding the higher prevalence of the presence of mucosal lesions, with 8.9% (95%
CI: 4.62% - 13.24%) of the cases in TL/HIV co-infection, than in cases of isolated TL, with
3.8% (95% CI: 3.50% - 4.19%; X<sup>2</sup>: 11.352; p-Value <0.001). The skin lesions were higher</li>
frequent in both (TL and TL/HIV), with almost 100%.

602 In the group with isolated TL, most patients had completed primary education (70.3%; 603 18,902), and 11.8% (3,185) were illiterate. The education field was ignored in 28.9% (10,927) of cases. Among patients with TL/HIV coinfection, 74.3% (78) had completed primary 604 605 education, 10.5% (11) were illiterate, and the education field was ignored in 37.5% (63). In the 606 isolated HIV group, education was more diverse: 36.6% (6,244) had incomplete primary 607 education, 25.6% (4,359) completed secondary education, 8.5% (1,446) had higher education, 608 and the education field was ignored in 36.6% (9,835) (Figure 20A). Significant differences 609 were observed between TL/HIV and isolated HIV, as well as between isolated TL and isolated 610 HIV (p<0.001), with TL groups showing a higher proportion of incomplete primary education. 611 However, no statistical significance was found between complete elementary and incomplete 612 high school (p=0.419) or between complete and incomplete higher education (p=0.126).

613 In the group with isolated TL, adults represented the majority (53.6%; 20,269), followed 614 by other age groups. Among TL/HIV coinfection cases, adults were also predominant (60.1%; 615 101). In the isolated HIV group, adults accounted for 88% (23,309), with the age group field 616 ignored in only 1.5% (408) of cases. Significant differences were observed between TL, 617 TL/HIV, and HIV groups (p<0.001), consistently reinforcing the predominance of adults across 618 all groups (Figure 20B). Statistical analysis between age groups showed significant distinctions 619 in all comparisons, including adolescents vs. adults, children vs. adults, and the elderly vs. other 620 groups (p<0.001), highlighting marked differences across age categories.



**Figure 20.** Characteristics associated with schooling (A) and age group (B) to the occurrence of TL/HIV, TL isolate, and HIV isolate co-infection from 2008 to 2022 in the state of Bahia.

In the isolated TL group, 97.9% (8,853) of patients were not pregnant, and 2.1% (193) were pregnant. Among TL/HIV coinfection cases, 96.6% (28) were not pregnant, and 3.4% (1) were pregnant. In contrast, in the isolated HIV group, 56.1% (5,968) were pregnant, and 43.9% (4,678) were not. The pregnant field was ignored or not applied in 76.1% (28,761) of TL cases, 82.7% (139) of TL/HIV cases, and 60.4% (16,242) of HIV cases. These differences (p<0.001) highlight a higher prevalence of pregnant women in the isolated HIV group, while non-pregnant women predominated in TL and TL/HIV groups.

629 Considering the data regarding race/color, in the isolated TL group, most patients 630 identified as brown (70.6%; 25,468), followed by black (21.5%; 7,743) and white (6.6%; 631 2,369). Among TL/HIV coinfection cases, 65.6% (103) were brown, 21% (33) were black, and 632 11.5% (18) were white. In the isolated HIV group, 60.8% (14,103) identified as brown, 26.7% 633 (6,189) as black, and 11.3% (2,619) as white. The race/color field was ignored or not applicable 634 in 4.6% (1,751) of TL cases, 6.5% (11) of TL/HIV cases, and 13.8% (3,703) of HIV cases. 635 Significant differences were observed between TL isolated and HIV isolated groups (p<0.001), 636 with a predominance of brown patients across all groups (Figure 21). Most comparisons 637 between race/color categories were statistically significant (p<0.001), except for yellow vs. 638 brown (p=0.169), yellow vs. black (p=0.318), and indigenous vs. brown (p=0.115), which 639 showed no significant differences.

Figure 21. Characteristics associated with race/color to the occurrence of TL/HIV, TL isolate,
 and HIV isolate co-infection from 2008 to 2022 in the state of Bahia.



642

643 In the isolated TL group, males predominated (59.8%; 22,588) compared to females 644 (40.2%; 15,203). Among TL/HIV coinfection cases, 64.9% (109) were male, and 35.1% (59) 645 were female. In the isolated HIV group, males represented 53.1% (14,260), and females 646 accounted for 46.9% (12,582). Unknown gender cases comprised 4.6% (16) in TL cases and 647 0.2% (46) in HIV cases. Significant differences were observed between TL isolated and HIV 648 isolated (p<0.001) and between TL/HIV coinfection and HIV isolated (p=0.003), highlighting 649 a higher prevalence of males across all groups. Statistical analysis also revealed significant 650 differences between sexes overall (p<0.001), reinforcing the trend of male predominance.

When analyzing the TL data, for the type of entry of the notified cases, it is observed that, for isolated TL, most cases are classified as new cases, with 93.69% (10,171), while in TL/HIV co-infection this frequency is lower, with 89.33% (134). Recurrence in co-infected patients represents 10.67% of cases (16), compared to 6.31% (685) in isolated TL. Notifications 655 marked as transfer and ignored were only observed in isolated TL cases, with absolute 656 frequencies of 68 and 61, respectively (**Table 4**).

Similarly, when analyzing the clinical form of reported cases, most isolated TL cases
were cutaneous (95.86%; 10,530), while this frequency was lower in TL/HIV coinfection
(88.24%; 135). The mucosal form was more frequent in coinfected patients (11.76%; 18)
compared to isolated TL (4.14%; 455). For confirmation criteria, laboratory confirmation was
predominant in isolated TL (65.59%; 7,205) and lower in TL/HIV coinfection (64.05%; 98).
The clinical-epidemiological criterion was used in 34.41% (3,780) of isolated TL cases and
35.95% (55) in coinfected cases (Table 4).

Regarding the epidemiological classification, most isolated TL cases were autochthonous (91.56%; n=10,058), with a lower frequency in TL/HIV coinfection (84.97%; n=130). Imported cases accounted for 3.57% (n=392) in isolated TL and 8.50% (n=13) in coinfected patients. Indeterminate cases were more frequent in isolated TL (4.87%; n=535) than in coinfection (6.54%; n=10) (**Table 4**).

669 Finally, with regard to the evolution of reported cases, most isolated TL cases were 670 discharged due to cure (95.51%; n=10,492), while this frequency was lower in TL/HIV 671 coinfection (88.89%; n=136). Cases of abandonment occurred in 97.60% (n=244) of isolated 672 TL cases and 3.92% (n=6) of coinfections. Deaths due to TL were recorded only in isolated TL 673 cases (100%; n=22). Deaths from other causes were more frequent in isolated TL (95.40%; 674 n=83) than in coinfection (4.60%; n=4). Transferred cases were also higher in isolated TL 675 (95.36%; n=144) compared to coinfection (4.64%; n=7) (**Table 4**). 676 Data on TL isolated and TL/HIV coinfection could not be compared by medications or

677 diagnostic methods due to the absence of these details in the analyzed database.

Table 4. Characteristics of initial drug administered, type of entry, types of diagnosis, and evolution in TL/HIV and TL coinfection from 2008 to
 2022 in the State of Bahia.

| Chamastanistia                 |                          |     | Coinfectio | on TL/HIV       |       | TL       |                 |  |  |
|--------------------------------|--------------------------|-----|------------|-----------------|-------|----------|-----------------|--|--|
| Characi                        | eristic                  | n   | Freq (%)   | CI 95%          | n     | Freq (%) | CI 95%          |  |  |
|                                | New case                 | 134 | 89.33      | (84.39 - 94.27) | 10171 | 93.69    | (93.23 - 94.15) |  |  |
| Input Type                     | Relapse                  | 16  | 10.67      | (5.73 - 15.61)  | 685   | 6.31     | (5.85 - 6.77)   |  |  |
| input Type                     | Transfer*                | 2   | -          | -               | 68    | -        | -               |  |  |
|                                | Ignored*                 | 1   | -          | -               | 61    | -        | -               |  |  |
|                                | Total                    | 150 |            |                 | 10856 |          |                 |  |  |
|                                |                          |     |            |                 |       |          |                 |  |  |
| Clinical Form                  | Skin                     | 135 | 88.24      | (83.13 - 93.34) | 10530 | 95.86    | (95.49 - 96.23) |  |  |
| Chinear Form                   | Mucosa                   | 18  | 11.76      | (6.66 - 16.87)  | 455   | 4.14     | (3.77 - 4.51)   |  |  |
|                                | Total                    | 153 |            |                 | 10985 |          |                 |  |  |
|                                |                          |     |            |                 |       |          |                 |  |  |
| Confirmation Criteria          | Clinical-Epidemiological | 55  | 35.95      | (28.34 - 43.55) | 3780  | 34.41    | (33.52 - 35.30) |  |  |
| Commination Criteria           | Laboratory               | 98  | 64.05      | (56.45 - 71.66) | 7205  | 65.59    | (64.7 - 66.48)  |  |  |
|                                | Total                    | 153 |            |                 | 10985 |          |                 |  |  |
|                                |                          |     |            |                 |       |          |                 |  |  |
|                                | Autochthonous            | 130 | 84.97      | (79.3 - 90.63)  | 10058 | 91.56    | (91.04 - 92.08) |  |  |
| Epidemiological Classification | Imported                 | 13  | 8.50       | (4.08 - 12.92)  | 392   | 3.57     | (3.22 - 3.92)   |  |  |
|                                | Indeterminate            | 10  | 6.54       | (2.62 - 10.45)  | 535   | 4.87     | (4.47 - 5.27)   |  |  |
|                                | Total                    | 153 |            |                 | 10985 |          |                 |  |  |
|                                |                          |     |            |                 |       |          |                 |  |  |
|                                | Abandonment              | 6   | 3.92       | (0.85 - 7.00)   | 244   | 2.22     | (1.95 - 2.50)   |  |  |
| Evolution                      | Discharged by cure       | 136 | 88.89      | (83.91 - 93.87) | 10492 | 95.51    | (95.12 - 95.90) |  |  |
| Evolution                      | Death from TL            | 0   | 0.00       | -               | 22    | 0.20     | (0.12 - 0.28)   |  |  |
|                                | Death from other causes  | 4   | 2.61       | (0.09 - 5.14)   | 83    | 0.76     | (0.59 - 0.92)   |  |  |

|      | Transfer | 7   | 4.58 | (1.26 - 7.89) | 144   | 1.31 | (1.10 - 1.52) |
|------|----------|-----|------|---------------|-------|------|---------------|
|      | Total    | 153 |      |               | 10985 |      |               |
| <br> |          | _   |      |               |       |      |               |

680 Legend 6. \*Not considered for frequency analysis; CI - Confidence Interval.

681 The overall mortality rate for isolated LT was 0.26 per 100,000 population, while the 682 mortality rate for LV/HIV coinfection was 0.03 per 100,000 population. As for deaths from 683 LT/HIV, they occurred entirely in the municipalities of Ibirataia, Itabuna, Jaborandi and Pau 684 Brasil, both with one death each, located in the south and west health regions, affecting 50% of 685 adults (2), 25% of children (1) and 25% of the elderly (1). Regarding sociodemographic 686 characteristics, 50% (02/04) of deaths were male and black, with 75% (3) of the victims having 687 only incomplete elementary education and one death having incomplete high school education. 688 Regarding TL, the case lethality rate remains constant over the years (around 0% and 689 0.40%), increasing during the years 2019 to 2022, with 0.21%, 0.30%, 0.26%, and 0.40%, 690 respectively. On the contrary, the lethality of AIDS had been a decrease over the years (from 691 10.66% to 1.80%). When compare lethality of both TL and TL/HIV co-infection over the years, 692 a significant and inverse correlation was observed (rho=-0.549, p=0.034, R<sup>2</sup>=0.176). In the case 693 of coinfection, there were records only in 2010, 2017 and 2018, with a lethality rate of 4.65%, 694 10% and 20%, respectively, which is higher than the other years (around 0%). There was no 695 significant correlation between lethality of TL/HIV co-infection and AIDS (rho=-0.232, 696 p=0.405, R<sup>2</sup>= 0.075) (Figure 22).

Figure 22. Annual lethality rate of TL, TL/HIV co-infection and AIDS in the state of Bahia.



Figure 23. Annual lethality rate of TL, TL/HIV co-infection and AIDS in the state of Bahia,Brazil.

Regarding the spatial distribution of TL, HIV and TL/HIV co-infection in the state, there is a distinction between the patterns of both diseases. It is observed that TL cases occurred with a higher incidence in the southern and western regions, while HIV cases were grouped in the coastal and extreme southern areas. In addition, cases of TL/HIV co-infection are present in focal sites, where their intensity is also related to the incidence of isolated VL, intercepting with these municipalities (**Figure 23**).

701



Figure 24. Spatial distribution of incidences of TL, HIV and TL/HIV coinfection bymunicipality in Bahia from 2008 to 2022.

710

The Moran Global autocorrelation indices for the incidence of TL isolated, HIV isolated, and TL/HIV co-infection were positive, with IMG: 0.619 (sd = 0.0280), IMG: 0.581 (sd = 0.0286) and IMG: 0.426 (sd = 0.0276), respectively.

When analyzing the incidence of isolated TL cases, significant areas of spatial dependence were also observed, with a high concentration of cases in 5.04% (21) of the municipalities located in the southern region, highlighted in dark red "High-High". Low or no prevalence was also observed in 28.06% (117) of the municipalities dispersed among the southwest, central-east, central-north, and north macro-regions (dark blue "Low-Low") (**Figure 24**).

In addition, regarding the incidence of isolated HIV cases, significant areas of spatial dependence were observed, as well as low or no incidence in 18.94% (79) of the municipalities in the southwest and west macro-regions (dark blue "Low-Low"), in addition to the high concentration of cases in 9.83% (41) of the municipalities, located in the south and far-south
macro-regions, highlighted in dark red "High-High" (Figure 24).

Finally, it is worth highlighting the incidence of TL/HIV co-infection, in which significant areas of spatial dependence were observed, with a high concentration of cases in 4.80% (20) of the municipalities located in the south and west regions, highlighted in dark red "High-High". A high incidence is also observed in the local and high chance in the neighboring municipality in 2.40% (10) of the municipalities dispersed among the macro-regions of the state (light red "High-Low") (**Figure 24**).





732

Moran's global bivariate index showed that the incidence of TL/HIV had a positive (direct) spatial correlation with the incidence of TL isolated (IMG: 0.462; sd = 0.0248). In the local results, it is observed that 41.37% (115) of the municipalities in the northern, southwestern, and western areas of the state showed a low-low pattern between the incidence of TL/HIV co-infection and the incidence of TL isolated. There was a predominance of direct correlation between TL/HIV co-infection and HIV isolated (IGM = 0.087; sd = 0.0223). Thus, the bivariate LISA shows that most municipalities (27.18%; 78) also had a low-low incidence of both diseases. Finally, the bivariate spatial correlation of TL isolated with HIV isolated, Moran's global statistic showed a positive correlation (IMG: 0.071; sd = 0.0214). Regarding the local Moran index, 27.87% (80) of the municipalities also had a low incidence of both diseases

743 (**Figure 25**).

- 744 Figure 26. Local bivariate spatial correlation of the incidences of: A TL/HIV co-infection and
- 745 TL isolated; B TL/HIV and HIV co-infection isolated; C TL isolated and HIV isolated in the
- 746 state of Bahia, 2008-2022.



747

Continuing with the analysis, the spatial associations related to TL/HIV co-infection and several socio-environmental variables were evaluated. In this sense, the association between TL/HIV co-infection and MHDI (A) was positive (IMG: 0.043; sd = 0.0212), with low-low clusters, mostly observed in 16.99% (52) of the municipalities, concentrated in areas of the
southwest, north, and central-north regions, indicating low incidence of the disease and low MHDI. As for the illiteracy rate (B), a significant inverse correlation was identified (IMG: -0.098; sd = 0.0216), reflecting a concentration of low-high patterns in 11.48% (38) of the municipalities, concentrated mainly in the northern region (**Figure 26**).

Regarding the percentage of households with access to piped water (C), the positive (direct) correlation observed (IMG: 0.017; sd = 0.0206) showed low-low clusters in 13.82% (42) of the municipalities. In the case of the percentage of persons in urban households served by household waste collection (D), the association was inverse (IMG: -0.066; sd = 0.0210). Low-high patterns represented 12.24% (42) of the localities, suggesting that the south and central-east regions have a low incidence of co-infection and a high percentage of household waste collection (**Figure 26**).

763 In relation to those employed in the agricultural sector (E), there was a direct correlation 764 (IMG: 0.063; sd = 0.0211), with high-high patterns present in 2.84% (9) of the municipalities, 765 concentrated in the southwest and south regions. This result demonstrates that the higher the 766 incidence of TL/HIV co-infection, the greater the professional activity in the agricultural sector. On the other hand, employment in the mining sector (F) showed a negative relationship (IMG: 767 768 -0.007; sd = 0.0215). Low-high clusters were observed in 6.42% (23) of the localities, indicating 769 low incidence of the disease and high occupation in the mining sector, grouped in the north and 770 east of the state (Figure 26).

Figure 27. Local bivariate spatial correlation of the incidence of TL/HIV co-infection with: A
- Municipal Human Development Index (MHDI); B – Illiteracy rate; C – Percentage of the
urban population residing in households connected to the water supply network; D – Percentage
of the urban population served by regular household waste collection services; E – Percentage

of those employed in the agricultural sector; F – Percentage of those employed in the mineral
 extractive sector, in the state of Bahia, period 2008-2022.



778 In continuity, the bivariate analysis of TL/HIV co-infection with mean rainfall (A) 779 revealed a negative (inverse) correlation (IMG: -0.062; sd = 0.0207), with low-high patterns 780 predominant in 26.96% (55) of the municipalities. This result demonstrates a low incidence of 781 the disease and an increase in the average rainfall in areas of the east, south and extreme south 782 regions of the state. For the mean temperature (B), a positive (direct) relationship was observed 783 (IMG: 0.060; sd = 0.0209). High-high clusters were recorded in 1.83% (4) of the municipalities, 784 indicating that vulnerability to co-infection may be associated with high temperatures (Figure 785 27).

777

Regarding the mean moisture content (C), the inverse correlation detected (IMG: -0.155;
sd = 0.0216) showed patterns of low-high LISA in 41.33% (81) of the municipalities, indicating
low incidence of the disease and an increase in the average humidity in areas of the eastern,
southern and extreme southern regions of the state. On the other hand, the GDP (D) showed a

positive association (IMG: 0.055; sd = 0.0218), with high-high LISA patterns located in 1.37%

(5) of the areas analyzed, predominating specifically in the southern region of the state of Bahia

792 (**Figure 27**).

793 In the case of the Gini index (E), which measures economic inequality, it showed a 794 direct correlation (IMG: 0.056; sd = 0.0215). High-high clusters corresponded to 1.85% (6) of 795 the municipalities, while low-low patterns were found in 13.89% (45), both found in the south 796 and southwest regions of the state, respectively. These results suggest that areas of greater 797 vulnerability to TL/HIV co-infection are associated with high socioeconomic inequality. 798 Finally, the unemployment rate (F) showed a negative (inverse) association (IMG: -0.015; sd = 799 0.0211), with low-high patterns predominant in 8.70% (30) of the municipalities in the west, 800 east, and south regions of the state (Figure 27).

Figure 28. Local bivariate spatial correlation of the incidence of TL/HIV co-infection with: A
Mean Rainfall; B – Average Temperature; C – Average Humidity; D – Gross Domestic
Product (GDP); E – Gini Index; F – Unemployment Rate, in the state of Bahia, period 20082022.



805

Moving forward in the analysis, the percentage of people living in poverty (A) showed a positive (direct) association (IMG: 0.059; sd = 0.0214). High-high clusters were present in 1.41% (4) of the north-central and western areas of the state. Regarding the proportion of people vulnerable to poverty (B), the correlation was also positive (IMG: 0.042; sd = 0.0213). Lowlow clusters accounted for 15.53% (48) of the localities, while high-high patterns were observed in 0.65% (2) of the municipalities. These results demonstrate the correlation of TL/HIV colinfection with poverty-related socioeconomic indicators (**Figure 28**).

813 For the percentage of people in extreme poverty (C), a positive (direct) association was 814 recorded (IMG: 0.079; sd = 0.0213). The high-high clusters corresponded to 1.90% (5) of the 815 areas located in the central and western regions of the state. In the case of the proportion of 816 people enrolled in CadÚnico or beneficiaries of Bolsa Família (D), the association was direct 817 (IMG: 0.055; sd = 0.0214). The LISA high-high clusters were present in 2.24% (7), covering 818 the areas of the central-north and south regions of the state of Bahia, indicating that in these 819 locations when there is a higher incidence of co-infection, there will also be a higher proportion 820 of people enrolled in social benefits (Figure 28). 821 Figure 29. Local bivariate spatial correlation of the incidence of TL/HIV co-infection with: A

822 – Percentage of Poor; B – Percentage of Vulnerable to Poverty; C – Percentage of Extremely



Poor; D – Percentage of people enrolled in CadÚnico or beneficiaries of Bolsa Família, in the
 state of Bahia, period 2008-2022.



- 826
- 827 Discussion

Not significant [263]

High-High [5]

Low-Low [67]

Low-High [69]

High-Low [13]

The analysis of VL and LT cases from 2008 to 2022 revealed changes in incidence, confirmation rate, HIV coinfection and case fatality between the two diseases. The findings suggest a general trend of reduction in VL cases over the years, while TL showed an initial increase followed by a more recent decline. The case confirmation rate also varied, being higher for LT compared to VL, which may indicate differences in diagnostic accuracy or quality of

Not significant [312]

High-High [7]

Low-Low [42]

Low-High [49] High-Low [7] reporting. Furthermore, although HIV coinfection was more frequent in VL than in LT, casefatality was high in both cases, especially in specific periods.

835 VL had a confirmation rate of 57.18%, indicating that almost half of the reported cases 836 were not confirmed. This discrepancy may be associated with the limitations of diagnostic 837 methods, which present variability in sensitivity and specificity (RODRIGUES et al., 2021), in 838 addition to possible failures in the reporting system, such as underreporting or duplicate records (HEWAWASAM et al., 2020; SILVA et al., 2016). On the other hand, TL had a significantly 839 840 higher confirmation rate (98.40%), suggesting greater diagnostic accuracy, possibly due to 841 more evident clinical manifestations and greater sensitivity of diagnostic tests, such as direct 842 parasitological examination widely available in the SUS (ESPIR et al., 2016; MEDEIROS et 843 al., 2024).

844 VL/HIV coinfection accounted for 2.30% of confirmed VL cases, indicating a relatively 845 low incidence. However, this association is clinically concerning, as both diseases increase the 846 severity of symptoms, make treatment difficult, and reduce patients' chances of recovery 847 (FONTES et al., 2024; LINDOSO et al., 2016). Most VL/HIV cases were classified as new 848 (83.33%), suggesting that coinfection occurs predominantly in individuals with no previous 849 history of leishmaniasis, which reinforces the hypothesis of greater immunological vulnerability in individuals immunosuppressed by HIV (AKUFFO et al., 2018). TL/HIV 850 851 coinfection was less frequent, representing only 0.48% of confirmed TL cases. Despite its low 852 incidence, this condition is also associated with a worse prognosis due to immunological 853 impairment and therapeutic difficulties (LINDOSO et al., 2016).

Regarding lethality, an increase was observed over the years for VL, reaching the highest rate in 2021 (13.33%). In relation to VL/HIV, there was a fluctuation in lethality rates, with higher rates in the years 2016, 2018 and 2012. Similarly, a survey carried out between 2007 and 2018 in Brazil identified a co-infection rate of 8.81% among individuals with VL, with a higher chance of death in older age groups and in the presence of HIV coinfection
(CARVALHO *et al.*, 2022). Similarly, AIDS mortality in Brazil has decreased, a fact attributed
to adherence to ART and health policies for prevention and treatment of HIV infection
(BATISTA *et al.*, 2023; SOUSA *et al.*, 2021).

For TL, the lethality remained stable between 0% and 0.40%, with an increase between 2019 and 2022. The lethality of TL/HIV was recorded only in 2010, 2017 and 2018, reaching peaks of 4.65%, 10% and 20%, respectively. A study indicates that co-infected patients may present atypical clinical manifestations and greater resistance to conventional treatment, which may result in higher lethality rates (RIBEIRO *et al.*, 2002).

As observed in other studies, HIV-induced immunosuppression alters both the clinical course and the therapeutic approach of TL. The management of these patients represents a significant challenge, since, compared with immunocompetent individuals, they have a higher frequency of therapeutic failure, greater susceptibility to drug toxicity, and higher mortality rates (ALVAR *et al.*, 2008; COUPPIÉ *et al.*, 2004).

Joinpoint regression analysis revealed an initial upward trend in the incidence of VL between 2007 and 2014, followed by a shift to a downward trend in the period from 2014 to 2022. However, these findings differ from national and regional studies, as well as other analyses conducted in the state of Bahia, which indicate a seasonal pattern in the incidence of the disease. This discrepancy may be due to differences in methodological approaches, or the specific periods analyzed in each study (ANDRADE; SOUZA; CARMO, 2022; BRUHN *et al.*, 2024).

For TL and TL/HIV, dynamic incidence patterns were demonstrated over time. The significant increase in TL cases until 2010, followed by a sharp decline until 2014, suggests the impact of public health interventions or changes in disease surveillance during this period. These results are similar to the study carried out at the national level, which identified an overall decrease in the number of cases, from 15.3 to 8.4 cases per 100,000 population (PORTELLA;
KRAENKEL, 2021). The stabilization of TL and TL/HIV cases after 2014 may indicate
changes in transmission dynamics, requiring further investigation.

886 However, it is possible that the observed trend is influenced by specific environmental 887 and climatic factors, such as deforestation, temperature variations, and humidity levels, which 888 can directly impact vector populations and disease transmission dynamics (BUZANOVSKY; 889 SANCHEZ-VAZOUEZ, 2020; NADIA et al., 2021). Additionally, socioeconomic conditions, 890 including access to healthcare, housing quality, and sanitation, may affect susceptibility and 891 exposure to TL. Therefore, continuous assessment of these variables is crucial to understanding their role in disease spread. Preventive strategies should be context-specific, focusing on 892 893 reducing vector habitats, improving living conditions, and enhancing public health 894 interventions aimed at mitigating transmission risks.

895 Regarding sex and age groups, for cases of isolated VL and VL/HIV, a higher incidence 896 is observed in males, with peaks in the age groups of 20 to 34 years and 35 to 49 years, and for 897 VL also in children aged 1 to 4 years. This pattern aligns with previous studies conducted in 898 Brazil and in states of the Northeastern Region (MACHADO et al., 2021b; SOUSA-GOMES 899 et al., 2011; VIANA et al., 2017). The higher incidence in adult males may be linked to 900 occupational exposure, outdoor activities, and greater mobility, which increase the likelihood 901 of contact with the vector (NINA et al., 2023; RIBEIRO et al., 2021). Additionally, the 902 prevalence of VL/HIV co-infection in young adults, particularly between 20 and 49 years, is 903 consistent with the epidemiology of HIV, where sexual transmission is the primary mode of 904 infection (CARVALHO et al., 2013; CLOOTS et al., 2021). This overlap suggests the need for 905 integrated surveillance and prevention strategies, particularly in vulnerable populations.

For isolated TL, the age pyramid reveals a higher incidence in males, with peaks in the age groups of 20 to 34 years, 35 to 49 years and 50 to 64 years. In the case of TL/HIV coinfection, there is a predominance of cases in men, concentrated mainly in the age groups of
35 to 49 years, 20 to 34 years and 50 to 64 years. These predisposition was also found in other
Regions of the country, such as state of Minas Gerais (Southeast Region) and Pernambuco
(Northeast Region), which show the profile of involvement in adult men of working age (BELO *et al.*, 2023; PINTO *et al.*, 2020; SILVA *et al.*, 2022).

913 In cases of isolated VL compared with VL/HIV coinfection there was significantly 914 higher the frequency of fever, such as found in a study conducted in the state of Tocantins 915 (COUTINHO et al., 2017), and edema frequency. Both symptoms reflect differences in the 916 inflammatory and immunological status of patients, suggesting that the immune response and 917 clinical profile may be influenced by the presence of HIV (TAKELE et al., 2023). For TL and 918 TL/HIV, mucosal lesions were more frequency in TL/HIV coinfection compared with isolated 919 TL. This finding is consistent with the literature, which associates coinfection with increased 920 severity of clinical manifestations and greater parasitic dissemination, in addition to treatment 921 failure due to the immunological deficiency caused by HIV (AMATO et al., 2009, 2024).

922 Regarding treatment, pentavalent antimonial continues to be the first-choice drug for 923 the treatment of VL, following the guidelines of the manual for the surveillance and control of 924 VL; however, it presents several toxic effects (BRASIL, 2014). In contrast, for the treatment of 925 VL/HIV coinfection, Liposomal Amphotericin B and Amphotericin B were used, respectively, 926 following the recommendations of the manual of recommendations for diagnosis, treatment and 927 monitoring of patients with leishmania-HIV coinfection (BRASIL, 2015). The absence of 928 recorded treatment in 2.84% of cases of VL/HIV coinfection may indicate missing data in the 929 records or clinical decisions influenced by patient conditions. This could be due to challenges 930 in diagnosis, disease severity, or other factors affecting treatment initiation. Further 931 investigations are needed to clarify the reasons behind these cases. It is worth noting that 932 therapeutic failures are observed in coinfection, demonstrating a greater recurrence of the

933 disease, which can be minimized by advising adherence to antiretroviral therapy (ART)
934 (TAKELE *et al.*, 2023).

935 The data highlight that most cases of VL are classified as new, while in VL/HIV a higher 936 proportion of relapses is observed, and that could suggest that coinfection impacts the response 937 to treatment and increases the chance of disease reactivation.

The lower frequency of positive diagnoses in coinfection by methods such as parasitology and IFAT suggests low accuracy of that diagnosis on immunosuppressed patients, possibly due to the lower immune response, including hummoral (FONTOURA *et al.*, 2018). n addition, the extremely low cure rate in coinfection (10.84%), associated with higher mortality from other causes (72.29%), highlights the severity of the interaction between the protozoan of VL and HIV, reinforcing the need for specific therapeutic and early diagnostic approaches for this vulnerable population (MACHADO *et al.*, 2021b).

945 However, in the case of VL, liposomal amphotericin B was significantly more used in 946 relapses compared to pentavalent antimony and pentamidine, indicating a preference for this 947 drug in scenarios of greater severity or resistance, due to its characteristic of lower toxicity, 948 which supports adherence to treatment, as is suggested an Brazilian Ministry of Health 949 (BRASIL, 2014). There was a greater use of amphotericin B and liposomal amphotericin B 950 before deaths due to VL. There was greater use of amphotericin B and liposomal amphotericin 951 B before deaths from VL. Both drugs are considered second-line treatment to pentavalent 952 antimoniate, becoming the main options in more severe cases and being associated with the 953 development of resistance by parasites (KUMARI et al., 2022).

The distribution of medication used in each age groups highlighted a significant pattern: liposomal amphotericin B was more commonly used in the elderly, while pentavalent antimonial was predominant in children and adolescents. It is important to highlight that the selection of medication for treatment takes into account factors such as the presence of comorbidities, the severity of the clinical condition and the profile of associated side effects
(SCALZONE *et al.*, 2016). For example, liposomal amphotericin B is only recommended as
the first choice of treatment for patients aged 50 years and older, pregnant women and children
under 1 year (BRASIL, 2014).

In the case of VL/HIV coinfection, the use of pentavalent antimonial was significantly more frequent in new cases, which goes against the recommendations of the Ministry of Health, since the first-choice drug is amphotericin B. For the visceral form, the use of the liposomal formulation is recommended as a priority, while, in the tegumentary form, amphotericin B deoxycholate is indicated, both for cutaneous and mucosal manifestations (BRASIL, 2015).

967 Therefore, in the case of TL and TL/HIV, relapse was more frequent in co-infection, 968 suggesting difficulties in the clinical management of these patients, associated with factors such 969 as immunosuppression and greater severity of the disease. Co-infection of both diseases results 970 in complex immunological interactions that can worsen the clinical condition of patients 971 (RIBEIRO et al., 2002). This immunological alteration favors the replication and dissemination 972 of Leishmania in the organism, resulting in more severe and disseminated clinical 973 manifestations of leishmaniasis in co-infected individuals. Although deaths from TL were 974 observed exclusively in isolated cases, deaths from other causes were more frequent in co-975 infected individuals, indicating an influence of HIV-related conditions on mortality, especially 976 when there is no adherence to ART (SHAW; MATIN, 2022).

VL cases are more prevalent in central and western areas, where climatic and ecological
conditions favor the presence of the vector and the disease reservoir (CARDENAS *et al.*, 2006;
MACHADO *et al.*, 2020b). In contrast, HIV cases are concentrated in the coastal and extreme
southern regions, areas associated with higher population density, urbanization, and social
vulnerability factors, such as sex tourism (OLIVEIRA-FILHO *et al.*, 2020; QUEVEDOGÓMEZ *et al.*, 2020).

Similarly, TL has a higher incidence in the southern and western regions, associated with environmental conditions favorable to the vector. TL/HIV co-infection occurs in focal locations, the intensity of which is directly related to the incidence of isolated TL and overlaps with municipalities with a high incidence of HIV, creating high-risk areas. Similar results were found in a study carried out in 2018 in Bahia, which also identified specific regions for the predominant occurrence of each form of leishmaniasis. Both can coexist in overlapping areas, and even at the municipal level, risk levels can vary significantly (RODGERS *et al.*, 2019).

For access to piped water, a positive correlation was identified, highlighting the relevance of urban conditions in increasing the incidence of co-infection. On the other hand, solid waste collection presented an inverse correlation, showing that better sanitation conditions are associated with a lower incidence of co-infection. It is clear that urban development without planning for ecologically correct measures, which considers trade-offs between agriculture, urbanization and conservation, leads to an increase in the incidence of VL and, consequently, to an increase in VL/HIV co-infection (SANTOS *et al.*, 2021).

997 Occupation in the agricultural sector showed a correlation, indicating that regions with 998 greater agricultural activity have a higher incidence of co-infection, possibly due to exposure 999 to the vector in rural areas. In recent years, rapid deforestation has allowed the advancement of 1000 agriculture and livestock farming, thus presenting high risks of irreversible changes in 1001 biodiversity and ecosystems (ESPÍRITO-SANTO *et al.*, 2020; OLIVEIRA *et al.*, 2017).

It is known that under high temperature conditions, the life cycle of sandflies is accelerated, resulting in a faster maturation process (BRASIL, 2014) and higher temperatures favor the transmission of co-infection. On the other hand, the results of the correlation between co-infection and humidity differ from studies carried out, which show that the population density of sandflies is affected by abiotic variables such as temperature, precipitation and humidity, and more humid environments can favor the proliferation of these vectors (COSTA *et al.*, 2013)

1009 Studies indicate that economic inequality can aggravate vulnerability to co-infection, as 1010 populations in poverty often lack adequate access to health services and live in conditions that 1011 facilitate the spread of the disease (HOUWELING et al., 2016; RIBEIRO et al., 2021; 1012 VALERO; PRIST; URIARTE, 2021) In addition, although social programs such as Bolsa 1013 Família seek to mitigate the effects of poverty, dependence on these aids may indicate continued 1014 exposure to risk factors associated with co-infection. On the other hand, economically more 1015 prosperous areas may have a higher incidence of co-infection, possibly due to urbanization and 1016 better access to diagnosis, which increases case reporting (SILVA et al., 2024)

1017 In addition, lower unemployment rates may be related to greater occupational exposure 1018 to the vector in rural or peri-urban activities, especially in sectors such as agriculture and civil 1019 construction (BOZORG-OMID *et al.*, 2023; MSELLEMU *et al.*, 2024)

Finally, the study faced limitations associated with the use of secondary data, such as the presence of gaps and incomplete information on notification forms, as well as inadequately completed records. Despite these constraints, the wide availability of data mitigated possible information losses, ensuring the robustness of the analyses performed.

1024

# 1025 Conclusion

1026 This study provided a comprehensive epidemiological and spatiotemporal analysis of 1027 VL, TL, and their co-infections with HIV in the state of Bahia, Brazil, from 2008 to 2022. The 1028 findings highlighted disparities in incidence, mortality, and spatial distribution across different 1029 regions and population groups. Concentrations of VL cases were observed in the central and 1030 western regions of Bahia, while TL cases predominated in the southern and western regions. In 1031 addition, VL/HIV and TL/HIV cases were widely dispersed, often overlapping with regions of 1032 high VL incidence. Men were more frequently affected by all diseases, with the highest concentration in the 20–49 age group. Educational levels varied, with the majority of VL and VL/HIV patients having only primary education. Clinically, VL/HIV patients had a lower prevalence of fever and edema compared to isolated VL cases, while TL/HIV patients showed a higher frequency of mucosal lesions. Furthermore, a positive spatial correlation was found between VL/HIV incidence and MHDI, access to piped water, and employment in the agricultural sector. Climatic factors also played a role, with high temperatures showing a positive correlation with VL/HIV.

1040 These findings reinforce the complex interplay between epidemiological, 1041 environmental, and sociodemographic factors in the transmission and progression of 1042 leishmaniasis and HIV coinfection. Therefore, improved surveillance and early detection 1043 strategies, especially in high incidence areas, are needed, as well as integrated public health 1044 policies that address the social determinants of health.

Finally, by assessing disease trends from 2008 to 2022, this study contributes information for future epidemiological monitoring and health policy planning in the state of Bahia. The integration of leishmaniasis and HIV control programs, with an emphasis on vulnerable populations, remains essential to reduce the burden of disease and improve health outcomes.

# REFERÊNCIAS

AGUIAR, P. F.; RODRIGUES, R. K. Leishmaniose visceral no Brasil: artigo de revisão. **Unimontes Científica**, v. 19, n. 1, p. 191–204, 2017. Disponível em: <a href="http://ruc.unimontes.br/index.php/unicientifica/article/view/526/406">http://ruc.unimontes.br/index.php/unicientifica/article/view/526/406</a>>.

AKUFFO, H.; COSTA, C.; VAN GRIENSVEN, J.; BURZA, S.; MORENO, J.; HERRERO,
M. New insights into leishmaniasis in the immunosuppressed. PLoS Neglected Tropical
Diseases, v. 12, n. 5, p. 1–16, 2018.

ALVAR, J.; APARICIO, P.; ASEFFA, A.; DEN BOER, M.; CAÑAVATE, C.; DEDET, J. P.; GRADONI, L.; TER HORST, R.; LÓPEZ-VÉLEZ, R.; MORENO, J. The relationship between leishmaniasis and AIDS: The second 10 years. **Clinical Microbiology Reviews**, v. 21, n. 2, p. 334–359, 2008.

AMATO, V. S.; FRANCO, L. A. M.; SOUZA, R. M. de; SILVA, C. A. M. da; RAMUNDO, M. S.; CÔRTES, M. F.; CORRÊA-CASTRO, G.; SANTOS-OLIVEIRA, J. R.; DA-CRUZ, A. M.; PAGLIARI, C.; GALO, L. K.; TUON, F. F. Case Report: In Situ and Systemic Immune Response to Mucosal Leishmaniasis in an HIV-Infected Patient. **American Journal** of Tropical Medicine and Hygiene, v. 110, n. 2, p. 228–233, 2024.

AMATO, V. S.; TUON, F. F.; IMAMURA, R.; ABEGÃO DE CAMARGO, R.; DUARTE, M. I.; NETO, V. A. Mucosal leishmaniasis: Description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. **Journal of the European Academy of Dermatology and Venereology**, v. 23, n. 9, p. 1026–1034, 2009.

ANDRADE, A. W. F.; SOUZA, C. D. F.; CARMO, R. F. Temporal and spatial trends in human visceral leishmaniasis in an endemic area in Northeast Brazil and their association with social vulnerability. **Transactions of the Royal Society of Tropical Medicine and Hygiene**, v. 116, n. 5, p. 469–478, 2022.

BANGERT, M.; MOLYNEUX, D. H.; LINDSAY, S. W.; FITZPATRICK, C.; ENGELS, D. The cross-cutting contribution of the end of neglected tropical diseases to the sustainable development goals. **Infectious Diseases of Poverty**, v. 6, n. 1, p. 1–20, 2017.

BARBOSA, D. S.; BELO, V. S.; RANGEL, M. E. S.; WERNECK, G. L. Spatial analysis for

identification of priority areas for surveillance and control in a visceral leishmaniasis endemic area in Brazil. **Acta Tropica**, v. 131, n. 1, p. 56–62, 2014. Disponível em: <a href="http://dx.doi.org/10.1016/j.actatropica.2013.12.002">http://dx.doi.org/10.1016/j.actatropica.2013.12.002</a>>.

BATISTA, J. F. C.; OLIVEIRA, M. R.; PEREIRA, D. L. M.; MATOS, M. L. S. da S.; DE SOUZA, I. T.; MENEZES, M. O. Spatial distribution and temporal trends of AIDS in Brazil and regions between 2005 and 2020. **Revista Brasileira de Epidemiologia**, v. 26, n. 1, p. 1–8, 2023.

BELO, V. S.; BRUHN, F. R. P.; BARBOSA, D. S.; CÂMARA, D. C. P.; SIMÕES, T. C.; BUZANOVSKY, L. P.; DUARTE, A. G. S.; MELO, S. N. de; CARDOSO, D. T.; DONATO, L. E.; MAIA-ELKHOURY, A. N. S.; WERNECK, G. L. Temporal patterns, spatial risks, and characteristics of tegumentary leishmaniasis in Brazil in the first twenty years of the 21st Century. **PLoS Neglected Tropical Diseases**, p. 1–18, 2023.

BENCHIMOL, J. L.; JOGAS JUNIOR, D. G. **Uma história das leishmanioses no novo mundo: fins do século XIX aos anos 1960**. Rio de Janeiro: Editora FIOCRUZ, 2020. 790 p.

BOZORG-OMID, F.; KAFASH, A.; JAFARI, R.; AKHAVAN, A. A.; RAHIMI, M.; RAHIMI FOROUSHANI, A.; YOUSSEFI, F.; SHIRZADI, M. R.; OSTADTAGHIZADEH, A.; HANAFI-BOJD, A. A. Predicting current and future high-risk areas for vectors and reservoirs of cutaneous leishmaniasis in Iran. **Scientific Reports**, v. 13, n. 1, p. 1–16, 2023.

BRASIL, M. da S. do B. Abordagens Espacias na Saúde Pública. p. 139, 2006.

BRASIL, M. da S. do B. Leishmaniose Tegumentar (LT). 2023. Disponível em: <a href="https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/l/lt>">https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/l/lt></a>.

BRASIL, M. da S. S. de V. em S. D. de I. e D. T. Manual de vigilância e controle da leishmaniose visceral. [s.l: s.n.]122 p.

BRASIL, M. da S. S. de V. em S. D. de I. e D. T. Manual de recomendações para diagnóstico, tratamento e acompanhamento de pacientes com a coinfecção leishmania-HIV. [s.l: s.n.]111 p.

BRUHN, F. R. P.; WERNECK, G. L.; BARBOSA, D. S.; CÂMARA, D. C. P.; SIMÕES, T. C.; BUZANOVSKY, L. P.; DUARTE, A. G. S.; DE MELO, S. N.; CARDOSO, D. T.;

DONATO, L. E.; MAIA-ELKHOURY, A. N. S.; BELO, V. S. Spatio-temporal dynamics of visceral leishmaniasis in Brazil: A nonlinear regression analysis. **Zoonoses and Public Health**, v. 71, n. 2, p. 144–156, 2024.

BURZA, S.; CROFT, S. L.; BOELAERT, M. Leishmaniasis – Authors' reply. **The Lancet**, v. 393, n. 10174, p. 872–873, 2019. Disponível em: <a href="http://dx.doi.org/10.1016/S0140-6736(18)33057-5">http://dx.doi.org/10.1016/S0140-6736(18)33057-5</a>>.

BUZANOVSKY, L. P.; SANCHEZ-VAZQUEZ, M. J. Major environmental and socioeconomic determinants of cutaneous leishmaniasis in Brazil – a systematic literature review. Journal of the Brazilian Society of Tropical Medicine, v. 53, n. e20190291, p. 1–8, 2020.

CARDENAS, R.; SANDOVAL, C. M.; RODRÍGUEZ-MORALES, A. J.; FRANCO-PAREDES, C. Impact of climate variability in the occurrence of leishmaniasis in Northeastern Colombia. **American Journal of Tropical Medicine and Hygiene**, v. 75, n. 2, p. 273–277, 2006.

CARVALHO, F. L.; AIRES, D. L. S.; SEGUNDA, Z. F.; AZEVEDO, C. M. P. E. S. De; CORRÊA, R. D. G. C. F.; DE AQUINO, D. M. C.; CALDAS, A. D. J. M. The epidemiological profile of HIV-positive individuals and HIV-Leishmaniasis co-infection in a referral center in São Luis, Maranhão, Brazil. **Ciência & Saúde Coletiva**, v. 18, p. 1305– 1312, 2013.

CARVALHO, L. S.; DAS GRAÇAS BRAGA, M.; DA SILVA COSTA, D. A.; SIMÕES, T. C.; LULA, M. D.; SILVEIRA, M. R. Lethality among individuals infected with visceral leishmaniasis in Brazil: a retrospective study (2007–2018). **Parasitology Research**, v. 121, n. 2, p. 725–736, 2022. Disponível em: <a href="https://doi.org/10.1007/s00436-022-07429-3">https://doi.org/10.1007/s00436-022-07429-3</a>>.

CHARLTON, R. L.; ROSSI-BERGMANN, B.; DENNY, P. W.; STEEL, P. G. Repurposing as a strategy for the discovery of new anti-leishmanials: The-state-of-the-art. **Parasitology**, v. 145, n. 2, p. 219–236, 2018.

CLOOTS, K.; MARINO, P.; BURZA, S.; GILL, N.; BOELAERT, M.; HASKER, E. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased Leishmania Transmission at the Village Level in Bihar, India. **Frontiers in Cellular and Infection Microbiology**, v. 11, n. March, p. 1–7, 2021.

COSTA, C. H. N. Characterization and speculations on the urbanization of visceral leishmaniasis in Brazil. **Cadernos de Saude Publica**, v. 24, n. 12, p. 2959–2963, 2008.

COSTA, P. L.; DANTAS-TORRES, F.; DA SILVA, F. J.; GUIMARÃES, V. C. F. V.; GAUDÊNCIO, K.; BRANDÃO-FILHO, S. P. Ecology of Lutzomyia longipalpis in an area of visceral leishmaniasis transmission in north-eastern Brazil. **Acta Tropica**, v. 126, n. 2, p. 99– 102, 2013.

COUPPIÉ, P.; CLYTI, E.; SOBESKY, M.; BISSUEL, F.; DEL GIUDICE, P.; SAINTE-MARIE, D.; DEDET, J. P.; CARME, B.; PRADINAUD, R. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIVinfected patients in French Guiana. **British Journal of Dermatology**, v. 151, n. 6, p. 1165– 1171, 2004.

COUTINHO, J. V. S. C.; DOS SANTOS, F. S.; RIBEIRO, R. D. S. P.; OLIVEIRA, I. B. B.; DANTAS, V. B.; SANTOS, A. B. F. S.; TAUHATA, J. R. Visceral leishmaniasis and Leishmaniasis-HIV coinfection: Comparative study. **Revista da Sociedade Brasileira de Medicina Tropical**, v. 50, n. 5, p. 670–674, 2017.

EHRENBERG, J. P.; AULT, S. K. Neglected diseases of neglected populations: Thinking to reshape the determinants of health in Latin America and the Caribbean. **BMC Public Health**, v. 5, p. 1–13, 2005.

ESPIR, T. T.; GUERREIRO, T. S.; NAIFF, M. de F.; FIGUEIRA, L. de P.; SOARES, F. V.; DA SILVA, S. S.; FRANCO, A. M. R. Evaluation of different diagnostic methods of American Cutaneous Leishmaniasis in the Brazilian Amazon. **Experimental Parasitology**, v. 167, p. 1–6, 2016. Disponível em: <a href="http://dx.doi.org/10.1016/j.exppara.2016.04.010">http://dx.doi.org/10.1016/j.exppara.2016.04.010</a>>.

ESPÍRITO-SANTO, M. M. do; ROCHA, A. M.; LEITE, M. E.; SILVA, J. O.; SILVA, L. A. P.; SANCHEZ-AZOFEIFA, G. A. Biophysical and Socioeconomic Factors Associated to Deforestation and Forest Recovery in Brazilian Tropical Dry Forests. **Frontiers in Forests and Global Change**, v. 3, n. December, p. 1–16, 2020.

FERREIRA, G. R.; RIBEIRO, J. C. C. B.; FILHO, A. M.; DE PEREIRA, T. J. C. F.;PARENTE, D. M.; PEREIRA, H. F.; DA SILVA, J. C.; ZACARIAS, D. A.; DA SILVA, L.V.; FAUSTINO, S. K. M.; NETO, W. S. A.; COSTA, D. L.; MENDONCA, I. L. De;COSTA, C. H. N. Human Competence to transmit leishmania infantum to lutzomyia

longipalpis and the influence of human immunodeficiency virus infection. American Journal of Tropical Medicine and Hygiene, v. 98, n. 1, p. 126–133, 2018.

FONTES, J. L. M.; KHOURI, R.; REINALDO, L. G. C.; HASSEGAWA, E. M. A.; FILHO, A. J. M.; DE MELO, C. V. B.; RAMOS, P. I. P.; MOURA, R. de D.; PAGLIARI, C.; SANTOS, M.; ARAÚJO, R. J. C.; VAN WEYENBERGH, J.; DE FREITAS, L. A. R.; COSTA, C. H. N.; DOS-SANTOS, W. L. C. An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection. **PLoS Neglected Tropical Diseases**, v. 18, n. 6, p. 1–16, 2024.

FONTOURA, I. G.; BARBOSA, D. S.; DE ANDRADE PAES, A. M.; SANTOS, F. S.; NETO, M. S.; FONTOURA, V. M.; COSTA, J. M. L.; SILVA, A. L. A. Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review. **Parasitology**, v. 145, n. 14, p. 1819, 2018.

GUERRA, J. A. O.; COELHO, L. I. R. C.; PEREIRA, F. R.; SIQUEIRA, A. M.; RIBEIRO, R. L.; ALMEIDA, T. M. L.; LACERDA, M. V. G.; BARBOSA, M. D. G. V.; TALHARI, S. American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon. **American Journal of Tropical Medicine and Hygiene**, v. 85, n. 3, p. 524–527, 2011.

HEWAWASAM, C.; WEERAKOON, H. S.; THILAKAN, V.; LELWALA, T.; PRASANKA, K.; RATHNAYAKA, A. S.; GAMAGE, S.; AGAMPODI, S. Is leishmaniasis adequately notified in Sri Lanka? A survey among doctors from an endemic district, Sri Lanka. **BMC Public Health**, v. 20, n. 1, p. 1–6, 2020.

HOTEZ, P. J. NTDs V.2.0: "Blue Marble Health"-Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape. **PLoS Neglected Tropical Diseases**, v. 7, n. 11, 2013.

HOUWELING, T. A. J.; KARIM-KOS, H. E.; KULIK, M. C.; STOLK, W. A.; HAAGSMA, J. A.; LENK, E. J.; RICHARDUS, J. H.; DE VLAS, S. J. Socioeconomic Inequalities in Neglected Tropical Diseases: A Systematic Review. **PLoS Neglected Tropical Diseases**, v. 10, n. 5, p. 1–28, 2016.

INCEBOZ, T. Epidemiology and Ecology of Leishmaniasis. Current Topics in Neglected

Tropical Diseases, v. 194, n. 1, p. 32–36, 2019.

JIRMANUS, L.; GLESBY, M. J.; GUIMARATES, L. H.; LAGO, E.; ROSA, M. E.; MACHADO, P. R.; CARVALHO, E. M. Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (viannia) braziliensis transmission over a 20-year period. **American Journal of Tropical Medicine and Hygiene**, v. 86, n. 3, p. 426– 433, 2012.

KASSAMBARA, A. **rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package version 0.7.2.**2023. Disponível em: <a href="https://cran.r-project.org/package=rstatix">https://cran.r-project.org/package=rstatix</a>.

KUMARI, D.; PERVEEN, S.; SHARMA, R.; SINGH, K. Advancement in leishmaniasis diagnosis and therapeutics : An update. **European Journal of Pharmacology**, v. 910, n. August, p. 174436, 2021. Disponível em: <a href="https://doi.org/10.1016/j.ejphar.2021.174436">https://doi.org/10.1016/j.ejphar.2021.174436</a>>.

KUMARI, S.; KUMAR, V.; KUMAR, R.; RAVIDAS, V.; PANDEY, K.; KUMAR, A. Amphotericin B: A drug of choice for Visceral Leishmaniasis. **Acta Tropica**, v. 235, n. June, p. 106661, 2022. Disponível em: <a href="https://doi.org/10.1016/j.actatropica.2022.106661">https://doi.org/10.1016/j.actatropica.2022.106661</a>>.

LIMA, A. F. de; SANTOS, A. F. S. dos; CALHEIROS, T. R. S. P.; XAVIER JUNIOR, A. F. S.; OLIVEIRA, S. G. de. Leishmaniose Visceral: Perfil Epidemiológico Dos Casos No Município De Maceió, Alagoas No Período De 2011 a 2016. Interfaces Científicas - Saúde e Ambiente, v. 7, n. 3, p. 133, 2019.

LINDOSO, J. A. L.; CUNHA, M. A.; QUEIROZ, I. T.; MOREIRA, C. H. V. Leishmaniasis– HIV coinfection: Current challenges. **HIV/AIDS - Research and Palliative Care**, v. 8, p. 147–156, 2016.

LINDOSO, J. A. L.; MOREIRA, C. H. V.; CUNHA, M. A.; QUEIROZ, I. T. Visceral leishmaniasis and HIV coinfection: Current perspectives. **HIV/AIDS - Research and Palliative Care**, v. 10, p. 193–201, 2018.

LOPES, L. C.; TRINDADE, G. V. de M.; BEZERRA, J. M. T.; BELO, V. S.; MAGALHÃES, F. do C.; CARNEIRO, M.; BARBOSA, D. S. Epidemiological profile, spatial patterns and priority areas for surveillance and control of leishmaniasis in Brazilian border strip, 2009–2017. **Acta Tropica**, v. 237, n. October 2022, 2023. MACHADO, C. A. L.; SEVÁ, A. da P.; DANTAS-TORRES, F.; HORTA, M. C. Spatial analysis and epidemiological profile of visceral leishmaniasis, northeastern Brazil: A crosssectional study. **Acta Tropica**, v. 208, n. April, p. 105520, 2020a. Disponível em: <a href="https://doi.org/10.1016/j.actatropica.2020.105520">https://doi.org/10.1016/j.actatropica.2020.105520</a>>.

MACHADO, C. A. L.; SEVÁ, A. da P.; DANTAS-TORRES, F.; HORTA, M. C. Spatial analysis and epidemiological profile of visceral leishmaniasis, northeastern Brazil: A crosssectional study. **Acta Tropica**, v. 208, n. May, p. 105520, 2020b. Disponível em: <a href="https://doi.org/10.1016/j.actatropica.2020.105520">https://doi.org/10.1016/j.actatropica.2020.105520</a>>.

MACHADO, C. A. L.; SEVÁ, A. da P.; E SILVA, A. A. F. A.; HORTA, M. C. Epidemiological profile and lethality of visceral leishmaniasis/human immunodeficiency virus co-infection in an endemic area in Northeast Brazil. **Revista da Sociedade Brasileira de Medicina Tropical**, v. 54, n. November 2020, p. 1–8, 2021a.

MACHADO, C. A. L.; SEVÁ, A. da P.; SILVA, A. A. F. A. e; HORTA, M. C. Epidemiological profile and lethality of visceral leishmaniasis/human immunodeficiency virus co-infection in an endemic area in Northeast Brazil. **Revista da Sociedade Brasileira de Medicina Tropical**, v. 54, n. November 2020, p. 1–8, 2021b.

MADALOSSO, G.; FORTALEZA, C. M.; RIBEIRO, A. F.; CRUZ, L. L.; NOGUEIRA, P. A.; LINDOSO, J. A. L. American visceral leishmaniasis: factors associated with lethality in the state of são paulo, Brazil. **Journal of tropical medicine**, v. 2012, p. 281572, jan. 2012. Disponível em:

<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3449136&tool=pmcentrez&rend ertype=abstract>. Acesso em: 6 out. 2012.

MAHESHWARI, K. K.; BANDYOPADHYAY, D. Heterocycles in the Treatment of Neglected Tropical Diseases. **Current Medicinal Chemistry**, v. 28, n. 3, p. 472–495, 2020.

MAIA-ELKHOURY, A. N. S.; ROMERO, G. A. S.; VALADAS, S. Y. O. B.; SOUSA-GOMES, M. L.; LAULETTA LINDOSO, J. A.; CUPOLILLO, E.; RUIZ-POSTIGO, J. A.; ARGAW, D.; SANCHEZ-VAZQUEZ, M. J. Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort study: A challenging opportunity? **PLoS Neglected Tropical Diseases**, v. 13, n. 12, p. 1–18, 2019.

MANGIAFICO, S. S. rcompanion: Functions to Support Extension Education Program

**Evaluation. R package version 2.4.32.**2024. Disponível em: <a href="https://cran.r-project.org/package=rcompanion">https://cran.r-project.org/package=rcompanion</a>>.

MARTINS-MELO, F. R.; DA SILVEIRA LIMA, M.; ALENCAR, C. H.; RAMOS, A. N.; HEUKELBACH, J. Epidemiological patterns of mortality due to visceral leishmaniasis and HIV/AIDS co-infection in Brazil, 2000-2011. **Transactions of the Royal Society of Tropical Medicine and Hygiene**, v. 108, n. 6, p. 338–347, 2014a.

MARTINS-MELO, F. R.; LIMA, M. D. S.; RAMOS, A. N.; ALENCAR, C. H.; HEUKELBACH, J. Mortality and case fatality due to visceral leishmaniasis in Brazil: A nationwide analysis of epidemiology, trends and spatial patterns. **PLoS ONE**, v. 9, n. 4, 2014b.

MEDEIROS, F. A. C.; SOUZA FILHO, J. A.; PIMENTEL, M. I. F.; REIS, I. A.; MENEZES-SOUZA, D.; SILVA, A. F. da; MARCELINO, A. P. Evaluation of the public health laboratory network for tegumentary leishmaniasis in an endemic area of Brazil. **Rev. Inst. Med. trop. S. Paulo**, v. 66, n. 9, p. e70, 2024.

MELO, S. N. de; BARBOSA, D. S.; BRUHN, F. R. P.; CÂMARA, D. C. P.; SIMÕES, T. C.; BUZANOVSKY, L. P.; DUARTE, A. G. S.; MAIA-ELKHOURY, A. N. S.; CARDOSO, D. T.; DONATO, L. E.; WERNECK, G. L.; BELO, V. S. Spatio-temporal relative risks and priority areas for visceral leishmaniasis control in Brazil, between 2001 and 2020. Acta Tropica, v. 242, n. January, 2023.

MSELLEMU, D.; TANNER, M.; YADAV, R.; MOORE, S. J. Occupational exposure to malaria, leishmaniasis and arbovirus vectors in endemic regions: A systematic review. **Current Research in Parasitology and Vector-Borne Diseases**, v. 6, n. June, p. 100185, 2024.

NADIA, N.; VALERO, H.; PRIST, P.; URIARTE, M. Science of the Total Environment Environmental and socioeconomic risk factors for visceral and cutaneous leishmaniasis in São Paulo , Brazil. **Science of the Total Environment**, v. 797, p. 148960, 2021. Disponível em: <a href="https://doi.org/10.1016/j.scitotenv.2021.148960">https://doi.org/10.1016/j.scitotenv.2021.148960</a>>.

NCI, N. C. I. Joinpoint Regression Program (Version 5.2.0.1). Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute2023. Disponível em: <a href="https://surveillance.cancer.gov/joinpoint/">https://surveillance.cancer.gov/joinpoint/</a>>. NGOUATEU, O. B.; KOLLO, P.; RAVEL, C.; DEREURE, J.; KAMTCHOUING, P.; SAME-EKOBO, A.; VON STEBUT, E.; MAURER, M.; DONDJI, B. Clinical features and epidemiology of cutaneous leishmaniasis and Leishmania major/HIV co-infection in Cameroon: Results of a large cross-sectional study. **Transactions of the Royal Society of Tropical Medicine and Hygiene**, v. 106, n. 3, p. 137–142, 2012. Disponível em: <http://dx.doi.org/10.1016/j.trstmh.2011.10.012>.

NINA, L. N. da S.; CALDAS, A. de J. M.; SOEIRO, V. M. da S.; FERREIRA, T. F.; SILVA, T. C.; RABELO, P. P. C. Spatial-temporal distribution of visceral leishmaniasis in Brazil from 2007 to 2020. **Revista Panamericana de Salud Publica/Pan American Journal of Public Health**, v. 47, p. 1–10, 2023.

NUNES, B. E. B. R.; LEAL, T. C.; DE PAIVA, J. P. S.; DA SILVA, L. F.; DO CARMO, R. F.; MACHADO, M. F.; DE ARAÚJO, M. D. P.; SANTOS, V. S.; DE SOUZA, C. D. F. Social determinants of mortality due to visceral leishmaniasis in Brazil (2001-2015): An ecological study. **Revista da Sociedade Brasileira de Medicina Tropical**, v. 53, n. July, p. 0–1, 2020.

OKWOR, I.; UZONNA, J. E. The immunology of Leishmania/HIV co-infection. **Immunologic Research**, v. 56, n. 1, p. 163–171, 2013.

OLIVEIRA-FILHO, A. B.; SILVA, F. Q.; SANTOS, F. J. A.; CARDOSO, Y. M. N.; DI MICELI, J. F. F.; RESQUE, R. L.; SILVA-OLIVEIRA, G. C.; MARTINS, L. C.; PINHEIRO, L. M. L.; MACHADO, L. F. A.; PINTO, A. R.; LEMOS, J. A. R.; FISCHER, B.; KUPEK, E. Prevalence and risk factors for HIV-1 infection in people who use illicit drugs in northern Brazil. **Transactions of the Royal Society of Tropical Medicine and Hygiene**, v. 114, n. 3, p. 213–221, 2020.

OLIVEIRA, S. N. de; ABÍLIO DE CARVALHO JÚNIOR, O.; TRANCOSO GOMES, R. A.; FONTES GUIMARÃES, R.; MCMANUS, C. M. Deforestation analysis in protected areas and scenario simulation for structural corridors in the agricultural frontier of Western Bahia, Brazil. **Land Use Policy**, v. 61, p. 40–52, 2017. Disponível em: <a href="http://dx.doi.org/10.1016/j.landusepol.2016.10.046">http://dx.doi.org/10.1016/j.landusepol.2016.10.046</a>>.

ORGANIZAÇÃO PAN-AMERICANA DE SAÚDE, O. Atlas interativo de leishmaniose nas Américas: aspectos clínicos e diagnósticos diferenciais. [s.l: s.n.]582 p. PINTO, M. O. K. M.; OLIVEIRA, T. M. de; AGUIAR, A. N. de A.; PINTO, P. E. M.;
BARBOSA, D. S.; DINIZ, S. de A.; SILVA, M. X. Profile of American tegumentary
leishmaniasis in transmission areas in the state of Minas Gerais, Brazil, from 2007 to 2017.
BMC Infectious Diseases, v. 20, n. 153, p. 1–9, 2020.

PORTELLA, T. P.; KRAENKEL, R. A. Spatial-temporal pattern of cutaneous leishmaniasis in Brazil. **Infectious Diseases of Poverty**, v. 10, n. 1, p. 1–11, 2021. Disponível em: <a href="https://doi.org/10.1186/s40249-021-00872-x">https://doi.org/10.1186/s40249-021-00872-x</a>>.

QUEVEDO-GÓMEZ, M. C.; KRUMEICH, A.; ABADÍA-BARRERO, C. E.; VAN DEN BORNE, H. W. Social inequalities, sexual tourism and HIV in Cartagena, Colombia: An ethnographic study. **BMC Public Health**, v. 20, n. 1, p. 1–11, 2020.

REIS, L. L.; BALIEIRO, A. A. da S.; FONSECA, F. R.; GONÇALVES, M. J. F. Changes in the epidemiology of visceral leishmaniasis in Brazil from 2001 to 2014. **Revista da Sociedade Brasileira de Medicina Tropical**, v. 50, n. 5, p. 638–645, 2017.

RIBEIRO, C. J. N.; DOS SANTOS, A. D.; LIMA, S. V. M. A.; DA SILVA, E. R.; RIBEIRO, B. V. S.; DUQUE, A. M.; PEIXOTO, M. V. S.; DOS SANTOS, P. L.; DE OLIVEIRA, I. M.; LIPSCOMB, M. W.; DE ARAÚJO, K. C. G. M.; DE MOURA, T. R. Space-time risk cluster of visceral leishmaniasis in brazilian endemic region with high social vulnerability: An ecological time series study. **PLoS Neglected Tropical Diseases**, v. 15, n. 1, p. 1–20, 2021.

RIBEIRO, R. N. S.; SALARO, C. P.; RESENDE, P.; PAULA, C. D. R. de. American cutaneous leishmaniasis associated with HIV/AIDS: report of four clinical cases. **Revista da Sociedade Brasileira de Medicina Tropical**, v. 35, n. 6, p. 651–654, 2002.

RODGERS, M. de S. M.; BAVIA, M. E.; EICHOLD II, B.; SHIPMAN, C.; OWEN, N.; WINSTANLEY, H.; GORDON, M.; KARAPETYAN, M.; MARIANA NASCIMENTO SILVA, M.; DANIELA MADUREIRA TRABUCO CARNEIRO, D.; LOBATO CARDIM, L.; DA SILVA FONSECA, E.; BROOKS MALONE, J. Environmental risk factors of leishmaniasis in Bahia State, Brazil using NASA Earth observation satellites. **Revista do Instituto Adolfo Lutz**, v. 78, p. 1–7, 2019.

RODRIGUES, W. F.; MENDES, N. S.; DE CARVALHO RIBEIRO, P.; MENDES FILHO, D.; PARREIRA, R. C.; CHAVES, K. C. B.; DE ABREU, M. C. M.; MIGUEL, C. B. A critical review of the applicability of serological screening for Leishmaniasis in blood banks

in Brazil. Journal of Parasitic Diseases, v. 45, n. 1, p. 109–117, 2021.

ROQUETTE, R.; NUNES, B.; PAINHO, M. The relevance of spatial aggregation level and of applied methods in the analysis of geographical distribution of cancer mortality in mainland Portugal (2009-2013). **Population Health Metrics**, v. 16, n. 1, p. 1–12, 2018.

RSTUDIO TEAM. RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA.2023. Disponível em: <a href="https://posit.co">https://posit.co</a>.

SANGENITO, L. S.; DA SILVA SANTOS, V.; D'AVILA-LEVY, C. M.; BRANQUINHA, M. H.; SOUZA DOS SANTOS, A. L.; DE OLIVEIRA, S. S. C. Leishmaniasis and Chagas Disease – Neglected Tropical Diseases: Treatment Updates. **Current Topics in Medicinal Chemistry**, v. 19, n. 3, p. 174–177, 2019.

SANTOS, C. V. B. Dos; SEVÁ, A. D. P.; WERNECK, G. L.; STRUCHINER, C. J. Does deforestation drive visceral leishmaniasis transmission? A causal analysis. **Proceedings of the Royal Society B: Biological Sciences**, v. 288, n. 1957, p. 1–9, 2021.

SASIDHARAN, S.; SAUDAGAR, P. Leishmaniasis: where are we and where are we heading? **Parasitology Research**, v. 120, n. 5, p. 1541–1554, 2021.

SCALZONE, M.; RUGGIERO, A.; MASTRANGELO, S.; TROMBATORE, G.; RIDOLA, V.; MAURIZI, P.; RICCARDI, R. Hemophagocytic lymphohistiocytosis and visceral leishmaniasis in children: Case report and systematic review of literature. **Journal of Infection in Developing Countries**, v. 10, n. 1, p. 103–108, 2016.

SESAB, S. da S. do E. da B. **Boletim Epidemiológico da Leishmaniose Tegumentar no Estado da Bahia**Salvador. 2024. Disponível em: <a href="https://www.saude.ba.gov.br/wp-content/uploads/2017/11/boletimEpidimiologicoLeishmanioseTegumentar\_Julho2024-1.pdf">https://www.saude.ba.gov.br/wp-content/uploads/2017/11/boletimEpidimiologicoLeishmanioseTegumentar\_Julho2024-1.pdf</a>>.

SEVÁ, A. da P.; MAO, L.; GALVIS-OVALLOS, F.; OLIVEIRA, K. M. M.; OLIVEIRA, F. B. S.; ALBUQUERQUE, G. R. Spatio-temporal distribution and contributing factors of tegumentary and visceral leishmaniasis: A comparative study in Bahia, Brazil. **Spatial and Spatio-temporal Epidemiology**, v. 47, n. August, 2023.

SEVÁ, A. da P.; MAO, L.; GALVIS-OVALLOS, F.; TUCKER LIMA, J. M.; VALLE, D. Risk analysis and prediction of visceral leishmaniasis dispersion in São Paulo State, Brazil.

## PLoS Neglected Tropical Diseases, v. 11, n. 2, p. 1–17, 2017.

SHAW, J.; MATIN, N. Opportunistic infections in HIV. **Medicine (United Kingdom)**, v. 50, n. 5, p. 294–297, 2022. Disponível em: <a href="https://doi.org/10.1016/j.mpmed.2022.02.010">https://doi.org/10.1016/j.mpmed.2022.02.010</a>>.

SILVA, A. A. F. A. e; COSTA, J. M. B. da S.; DUARTE, M. S.; ALBUQUERQUE, A. C. de.
Programa de Vigilância e Controle da Leishmaniose Visceral: um estudo de avaliabilidade.
Physis: Revista de Saúde Coletiva, v. 34, p. 1–29, 2024.

SILVA, C. J. da; SUASSUNA, J. F. da C. L.; BRANDÃO-FILHO, S. P.; BRITO, M. E. F.
de. Study on the zoonotic cycle of tegumentary leishmaniasis in an endemic area of a metropolitan region in the Northeastern region of Brazil. Rev. Inst. Med. trop. S. Paulo, v. 64, p. 2–9, 2022.

SILVA, S. H. A. da; MOTA, J. C. da; SILVA, R. S. da; CAMPOS, M. R.; SCHRAMM, J. M. de A. Descrição dos registros repetidos no Sistema de Informação de Agravos de Notificação, Brasil, 2008-2009. **Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil**, v. 25, n. 3, p. 487–498, 2016.

SOUSA-GOMES, M. L. De; MAIA-ELKHOURY, A. N. S.; PELISSARI, D. M.; LIMA JUNIOR, F. E. F. de; SENA, J. M. De; CECHINEL, M. P. Coinfecção Leishmania-HIV no Brasil: aspectos epidemiológicos, clínicos e laboratoriais. **Epidemiol. Serv. Saúde**, v. 20, n. December, p. 519–526, 2011.

SOUSA-GOMES, M. L. de; ROMERO, G. A. S.; WERNECK, G. L. Visceral leishmaniasis and HIV/AIDS in Brazil: Are we aware enough? **PLoS Neglected Tropical Diseases**, v. 11, n. 9, p. 1–13, 2017.

SOUSA, A. C. L. de; ELEUTERIO, T. de A.; COUTINHO, J. V. A.; GUIMARÃES, R. M. Assessing antiretroviral therapy success in HIV/AIDS morbidity and mortality trends in Brazil, 1990–2017: an interrupted time series study. **International Journal of STD and AIDS**, v. 32, n. 2, p. 127–134, 2021.

SOUZA, E. A. de; BOIGNY, R. N.; OLIVEIRA, H. X.; OLIVEIRA, M. L. W.-D.-R. de; HEUKELBACH, J.; ALENCAR, C. H.; MARTINS-MELO, F. R.; RAMOS JÚNIOR, A. N. Tendências e padrões espaço-temporais da mortalidade relacionada à hanseníase no Estado da Bahia, Nordeste do Brasil, 1999-2014. **Cadernos Saúde Coletiva**, v. 26, n. 2, p. 191–202, 2018.

STEVERDING, D. The history of leishmaniasis. **Parasites and Vectors**, v. 10, n. 1, p. 1–10, 2017.

TAKELE, Y.; MULAW, T.; ADEM, E.; WOMERSLEY, R.; KAFOROU, M.; FRANSSEN, S. U.; LEVIN, M.; TAYLOR, G. P.; MÜLLER, I.; COTTON, J. A.; KROPF, P. Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load. **iScience**, v. 26, n. 2, 2023.

THAKUR, S.; JOSHI, J.; KAUR, S. Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. **Journal of Parasitic Diseases**, v. 44, n. 2, p. 253–272, 2020. Disponível em: <a href="https://doi.org/10.1007/s12639-020-01212-w">https://doi.org/10.1007/s12639-020-01212-w</a>.

TORRES-GUERRERO, E.; QUINTANILLA-CEDILLO, M. R.; RUIZ-ESMENJAUD, J.; ARENAS, R. Leishmaniasis : a review. v. 6, n. May, p. 1–15, 2017.

UNAIDS. Global AIDS Monitoring 2023. 2023. Disponível em: <a href="https://www.unaids.org/en/resources/documents/2022/global-aids-monitoring-guidelines-">https://www.unaids.org/en/resources/documents/2022/global-aids-monitoring-guidelines-</a>.

VALERO, N. N. H.; PRIST, P.; URIARTE, M. Environmental and socioeconomic risk factors for visceral and cutaneous leishmaniasis in São Paulo, Brazil. Science of the Total Environment, v. 797, p. 148960, 2021.

VIANA, G. M. de C.; DA SILVA, M. A. C. N.; GARCIA, J. V. de S.; GUIMARÃES, H. D.;
ARCOS JÚNIOR, G. F.; SANTOS, A. V. A.; DA PAIXÃO, P. V.; NASCIMENTO, M. do D.
S. B.; GALVÃO, C. de S. Epidemiological profile of patients co-infected with visceral leishmaniasis and HIV/AIDS in northeast, Brazil. Revista da Sociedade Brasileira de Medicina Tropical, v. 50, n. 5, p. 613–620, 2017.

WERNECK, G. L.; COSTA, C. H. N.; WALKER, A. M.; DAVID, J. R.; WAND, M.; MAGUIRE, J. H. Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil. **Caderno de Saude Pública**, v. 135, n. 2, p. 195–201, fev. 2007. Disponível em: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2870576&tool=pmcentrez&rend ertype=abstract>. Acesso em: 10 out. 2012.

WHO. Control of the leishmaniases. [s.l: s.n.]22-26 p.

WHO. Control of Neglected Tropical Diseases. 2019. Disponível em: <a href="https://www.who.int/teams/control-of-neglected-tropical-diseases">https://www.who.int/teams/control-of-neglected-tropical-diseases</a>>.

WHO. Leishmaniasis: the global trend. 2020. Disponível em: <a href="https://www.who.int/news/item/30-01-2009-leishmaniasis-the-global-trend">https://www.who.int/news/item/30-01-2009-leishmaniasis-the-global-trend</a>>.

# ANEXO A - Comitê de Ética em Pesquisa



### DADOS DO PROJETO DE PESQUISA

Titulo da Pesquisa: ANÁLISE EPIDEMIOLÓGICA E ESPACIAL DE CASOS DE LEISHMANIOSE VISCERAL E HIV EM COINFECÇÃO NO ESTADO DA BAHIA

Pesquisador: ANAIA DA PAIXAO SEVA Área Temática: Versão: 1 CAAE: 47443721.4.0000.5526 Instituição Proponente:Universidade Estadual de Santa Cruz Patrocinador Principal: Financiamento Próprio

#### DADOS DO PARECER

Número do Parecer: 4.784.218

#### Apresentação do Projeto:

O protocolo de pesquisa intitulado \* ANÁLISE EPIDEMIOLÓGICA E ESPACIAL DE CASOS DE LEISHMANIOSE VISCERAL E HIV EM COINFECÇÃO NO ESTADO DA BAHIA\*, apresentado pela pesquisadora "ANAIÁ DA PAIXÃO SEVA", sob número de CAAE 47443721.4.0000.5526, diz respeito a uma investigação científica realizada com dados secundários (casos de LV notificados no Estado da Bahia). Serão analisados os casos humanos suspeitos e confirmados com leishmaniose visceral com e sem coinfecção com HIV na Bahia, dentre os anos de 2003 e 2020.Os dados de cada paciente serão obtidos da Secretaria Estadual da Saúde do Estado da Bahia (SESAB). Serão analisadas características do perfil epidemiológico e espacial destas coinfecções, como: 1. Distribuição espaço-temporal de casos e das notificações; 2. Associação de fatores socioeconômicos; 3. Características epidemiológicas: sexo, faixa etária, raça/cor; 4. Tipos de entrada (caso novo e recidiva) e desfecho (oura, óbito) dos casos; 5. Tipo de tratamento; 6. Comparação da letalidade da LV e do HIV com ou sem coinfecção. Os resultados deste estudo, realizado na Universidade Estadual de Santa Cruz, serão disponibilizados para a SESAB em forma de boletim informativo.

#### Objetivo da Pesquisa:

De acordo com o protocolo submetido, o objetivo primário é realizar análises epidemiológicas e espaciais, no intuito de identificar o comportamento do HIV/AIDS e da Leishmaniose visceral e os

| Enderaço: | Campus Soarse Naz | aré de Andrada, Rodovis Ju | arge Amado, Km 16        |  |
|-----------|-------------------|----------------------------|--------------------------|--|
| Bairro: S | ALOBRINHO         | CEP                        | 45.862-900               |  |
| UF: BA    | Nunicipio:        | LHEUS                      |                          |  |
| Telefone: | (73)3680-5310     | Fax: (/3)3680-5319         | E-mail: top_uesc@uesc.br |  |

Págne 01 de 04



UNIVERSIDADE ESTADUAL DE SANTA CRUZ - UESC



Continuação do Parecer: 4.784.218

fatores associados aos casos de ambas de modo isolado e em coinfecção. O objetivo secundário é elucidar a dinâmica da Leishmaniose visoeral e do HIV/AIDS no estado da Bahia, acerca da distribuição geográfica das doenças, bem como associando fatores de risco ambientais, climáticos e socioeconômicos para ocorrência de tais infecções; identificar e comparar o perfil dos casos isolados e em co-infecção, bem como a letalidade, morbidade, taixa-etária, recidivas e abandono de tratamento. Também será avaliada a infecção concomitante e isolada de ambas no aspecto de município de residência e de notificação.

#### Avaliação dos Riscos e Beneficios:

Os riscos indicados pela pesquisadora se referem à quebra de sigilo dos dados dos pacientes. Entretanto, os riscos são mínimos para o caso de estudos, como este, que empregam técnicas e métodos retrospectivos de pesquisa e em que não se realiza nenhuma intervenção ou modificação intencional nas variáveis fisiológicas ou psicológicas e sociais dos indivíduos que participam no estudo.

Como beneficios, a pesquisadora aponta que serão definidos municípios sob risco de intensificar a ocorrência da doença e que, por tanto, irão requerer intervenções de prevenção e controle, assim como seus municípios vizinho. Nortear a aplicação mais eficaz de esforços e recursos para ações de prevenção, rastreio e controle da Leishmaniose visceral e da coinfecção Leishmania-HIV no estado da Bahia.

#### Comentários e Considerações sobre a Pesquisa:

Trata-se de uma pesquisa relevante para a saúde coletiva, dado o cenário epidemiológico apresentado pela LV no nordeste brasileiro e na Bahia, local do estudo. De acordo com o protocolo, as informações dos casos de LV serão provenientes de um banco de dados da SESAB e disponibilizadas à pesquisadora sem as variáveis nome e endereço, o que impede a identificação dos casos. Como não se trata de uma pesquisa realizada com diretamente com seres humanos, mas sim com dados da ocorrência de doenças, não há necessidade de autorização prévia dos participantes pelo processo de consentimento fivre e esclarecido.

#### Considerações sobre os Termos de apresentação obrigatória:

A pesquisadora apresenta os termos necessários:

 a) folha de rosto, devidamente preenchida e assinada pelo diretor do Departamento ao qual a pesquisadora se vincula;

b)Projeto de pesquisa na integra;

c) Termo de anuência da instituição que disponibilizará o banco de dados, devidamente assinado e

| Enderso  | e: Campus Soane Max | ré de Andrada, Rodovia Jurge | Arraeto, Km 16           |  |
|----------|---------------------|------------------------------|--------------------------|--|
| Bairro:  | SALOBRINHO          | CEP: 45                      | 862-900                  |  |
| UP: BA   | Nunicipio           | LHEUS                        |                          |  |
| Telefone | (73)3680-5319       | Fax: (/3)3680-5319           | E-mail: rsp_uesc@uesc.br |  |

Págne 00 de 04



UNIVERSIDADE ESTADUAL DE SANTA CRUZ - UESC



Continuação do Parecer: 4.764.218

carimbado por seu representante;

 d)Termo de compromisso de uso de dados assinado e carimbado pelos membros da equipe de pesquisa;
 e) Declaração de comprometimento de entrega dos documentos físicos relativos ao protocolo de pesquisa ao CEP assim que as medidas de distanciamento social forem flexibilizadas.

g) Curriculo Lattes dos pesquisadores

 h) Documento que justifica a dispensa de TCLE e TALE, uma vez que os dados do banco serão disponibilizados sem identificação.

#### Recomendações:

Não hà recomendações.

Conclusões ou Pendências e Lista de Inadequações:

Não há pendências no protocolo de pesquisa.

## Considerações Finais a critério do CEP:

O Comité de Ética em Pesquisa da UESC avaliou o Protocolo de Pesquisa "ANÁLISE EPIDEMIOLÓGICA E ESPACIAL DE CASOS DE LEISHMANIOSE VISCERAL E HIV EM COINFECÇÃO NO ESTADO DA BAHIA", CAAE 47443721.4.0000.5526, em reunião ordinária realizada em 16 de junho de 2021 e considerou que a proposta possui mérito científico e demonstra atender os requisitos atinentes á ética em pesquisa com seres humanos. Após relato e discussão do protocolo, este Colegiado emitiu parecer favorável à APROVAÇÃO. Havendo alterações necessárias no projeto, estas deverão ser encaminhadas à este CEP na forma de Emenda. No caso de eventos adversos, estes deverão ser notificados ao CEP. Solicitamos especial atenção no envio dos relatórios semestrais e final.

| Este parecer | foi elaborado base | ado nos documen | tos abaixo relacionados: |
|--------------|--------------------|-----------------|--------------------------|
|--------------|--------------------|-----------------|--------------------------|

| Tipo Documento                                   | Arquiva   | Postagem               | Autor                   | Situação |
|--|---|------------------------|-------------------------|----------|
| Informações Básicas<br>do Projeto                | PB_INFORMAÇÕES_BÁSICAS_DO_P<br>ROJETO 1733137 pdf | 24/05/2021 07:23:05    |                         | Aceilo   |
| Declaração de<br>Instituição e<br>Infraestrutura | Termo_de_Anuencia_Intitucional.pdf                | 24/05/2021<br>07:22:22 | ANAIA DA PAIXAO<br>SEVA | Aceito   |
| Projeto Detalhado /<br>Brochura<br>Investigador  | PROPP_Mod_Proj_Pesquisa_com_CEP<br>.pdf           | 19/05/2021<br>08:25:57 | ANAIA DA PAIXAO<br>SEVA | Aceito   |
| Declaração de<br>Pesquisadores                   | ResponsabilidadePesquisador.pdf                   | 17/05/2021 16:29:57    | ANAIA DA PAIXAO<br>SEVA | Aceito   |

| Enderaço: | Campus Soarse Naz | aré de Andrada, Rodovis Ji | urga Amado, Km 16        |  |
|-----------|-------------------|----------------------------|--------------------------|--|
| Bairro: S | ALOBRINHO         | CEP                        | 45.862-900               |  |
| UP: BA    | Municipio         | LHEUS                      |                          |  |
| Telefone: | (73)3680-5310     | Fax: (73)3680-5319         | E-mail: inp_uesc@uesc.br |  |

Págne 00 de 04



UNIVERSIDADE ESTADUAL DE



Continuação do Parecer: 4.764.218

| Declaração de<br>Pesquisadores                                     | DeclarComprometimento.pdf | 17/05/2021<br>16:17:58 | ANAIA DA PAIXAO<br>SEVA        | Aceilo |
|--|---------------------------|------------------------|--------------------------------|--------|
| TCLÉ / Termos de<br>Assentimento /<br>Justificativa de<br>Ausência | TCLE.pdf                  | 17/05/2021<br>15:39:16 | ANAIA DA PAIXAO<br>SEVA        | Aceito |
| TCLE / Termos de<br>Assentimento /<br>Justificativa de<br>Ausência | TALE.pdf                  | 17/05/2021<br>15:38:50 | ANAIA DA PAIXAO<br>SEVA        | Aceito |
| Declaração de<br>Pesquisadores                                     | CompromissoUsoDados.pdf   | 17/05/2021<br>15:33:41 | ANAIA DA PAIXAO<br>SEVA        | Acetto |
| Cutros   | LattesAnaia.pdf           | 17/05/2021<br>15:32:02 | ANAIA DA PAIXAO<br>SEVA        | Aceito |
| Folha de Rosto   | foihaDeRosto.pdf          | 17:05/2021<br>15:30:22 | ANAIA DA PAIXAO<br>SEVA        | Aceito |
| Outros   | lattesKayo.pdf            | 17.05/2021<br>14:56:04 | KAYO RESENDE<br>DIAS E ALMEIDA | Aceilo |

Situação do Parecer; Aprovado Necessita Apreciação da CONEP: Não

ILHEUS, 16 de Junho de 2021

Assinedo por: Maria Cristina Rangel (Coordenedor(a))

| Enderaço: | Campus Soarse Naz | aré de Andrada, Rodovie J | Jurge Amedo, Km 16       |  |
|-----------|-------------------|---------------------------|--------------------------|--|
| Bairro: S | ALOBRINHO         | CEP                       | 45.602-900               |  |
| UF: BA    | Nunicipio         | LHEUS                     |                          |  |
| Telefone: | (73)3680-5319     | Fax: (73)3680-5319        | E-mail: rep_uesc@uesc.tr |  |

Págna 04 de 04